



**Together Again:  
Connection, Reflection  
and Celebration**

**À nouveau réunis :  
connexions, réflexions,  
célébrations**

# **34<sup>TH</sup> EME** ANNUAL CONFERENCE **CONFÉRENCE ANNUELLE**



**OCTOBER 27-30, 2022**  
*Victoria Convention Centre and  
Fairmont Empress Hotel*

# It takes innovation

Pfizer Canada strives to profoundly impact the health of Canadians through the discovery, development and delivery of medicines and vaccines.

Research and development is at the heart of fulfilling Pfizer's purpose as we work to translate advanced science and technologies into the therapies that matter most.



[pfizer.ca](https://www.pfizer.ca)





**FOR MEN WITH**

**ADVANCED PROSTATE CANCER**

**Up to 1 in 5 men have a distinct disease **hiding** in plain sight<sup>1-6</sup>**

**Have you tested your patients for *BRCA* and *ATM* mutations?**

*BRCA* and *ATM* are part of a family of genes involved in DNA damage repair.<sup>1,5</sup>

Prostate cancer with mutations in the *BRCA* and *ATM* genes results in a more aggressive disease, leading to a decrease in patient survival.<sup>1-3,7-10</sup>

Consider testing for *BRCA* and *ATM* mutations in all men with advanced prostate cancer to inform prognosis, predict response to novel targeted therapies and assess familial cancer risk.

**TEST TO REVEAL**

***BRCA* and *ATM* mutations**

*ATM*=ataxia-telangiectasia mutated; *BRCA*=breast cancer 1/breast cancer 2

**References:** **1.** Abida W, Armenia J, Gopalan A, et al. Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making [published online May 31, 2017]. *JCO Precis Oncol*. 2017. doi:10.1200/PO.17.00029. **2.** Pezaro CJ, Marciscano AE, Madan RA. The winds of change: emerging therapeutics in prostate cancer. *Am Soc Clin Oncol Educ Book*. 2018;38:382-390. **3.** Na R, Zheng SL, Han M, et al. Germline mutations in *ATM* and *BRCA1/2* distinguish risk for lethal and indolent prostate cancer and are associated with early age at death. *Eur Urol*. 2017;71(5):740-747. **4.** Robinson D, Van Allen EM, Wu Y-M, Schultz N, Lonigro RJ, Mosquera J-M, et al. Integrative clinical genomics of advanced prostate cancer. *Cell*. 2015 May 21;161(5):1215-28. **5.** Pritchard CC, Mateo J, Walsh MF, et al. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. *N Engl J Med*. 2016;375(5):443-453. **6.** Beltran et al. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. *Eur Urol*. 2013 May;63(5):920-6. **7.** Castro et al. Germline *BRCA* mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. *J Clin Oncol*. 2013 May 10;31(14):1748-57. **8.** Castro et al. Effect of *BRCA* Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer. *Eur Urol*. 2015 Aug;68(2):186-93. **9.** Castro et al. A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients with Metastatic Castration-Resistant Prostate Cancer. *J Clin Oncol*. 2019 Feb 20;37(6):490-503. **10.** Taylor et al. Germline *BRCA2* mutations drive prostate cancers with distinct evolutionary trajectories. *Nat Commun* 8, 13671 (2017).



**MERCK**



# Your hematology oncology partner

Find out more at [Jazzpharma.com](https://www.jazzpharma.com)

**For more information:**

Please consult the respective Product Monographs at [jazzpharma.com/medicines/our-medicines/](https://www.jazzpharma.com/medicines/our-medicines/) for important information relating to adverse reactions, drug interactions, and dosing that has not been discussed in this piece. The Product Monographs are also available by calling us at 1-800-520-5568.

**NOW AVAILABLE IN CANADA!**

## Introducing our portfolio of products

  
daunorubicin and cytarabine  
liposome for injection



<sup>P</sup>**VYXEOS**® (daunorubicin and cytarabine liposome for injection) is indicated for the treatment of adults with newly diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

  
DEFITELIO®  
(defibrotide) injection  
80 mg/mL



<sup>P</sup>**DEFITELIO**® (defibrotide sodium) solution for intravenous infusion is indicated for the treatment of adult and pediatric patients with severe hepatic veno-occlusive disease (VOD) also known as sinusoidal obstruction syndrome (SOS), following hematology stem-cell transplantation (HSCT).

  
<sup>P</sup>**ZEPZELCA**®  
(lurbinectedin) for injection 4 mg



<sup>P</sup>**ZEPZELCA**® (lurbinectedin) is indicated for the treatment of adult patients with Stage III or metastatic SCLC (small cell lung cancer) who have progressed on or after platinum-containing therapy.

ZEPZELCA has been issued market authorization with conditions, pending the results of trials to verify its clinical benefit. Patients should be advised of the nature of the authorization. For further information for ZEPZELCA please refer to Health Canada's Notice of Compliance with conditions.

Please consult the Product Monograph for complete information about ZEPZELCA, including patient selection, adverse event management, and dosing details.

**References:** 1. ZEPZELCA® Product Monograph. Jazz Pharmaceuticals Canada, Inc. September 29, 2021. 2. VYXEOS® Product Monograph. Jazz Pharmaceuticals Canada, Inc. April 28, 2021. 3. DEFITELIO® Product Monograph. Jazz Pharmaceuticals Canada, Inc. August 14, 2020.

ZEPZELCA® is a registered trademark of PHARMA MAR, S.A., used under licence. VYXEOS® is a registered trademark of Celator Pharmaceuticals, Inc. (a Jazz Pharmaceuticals subsidiary). DEFITELIO® is a registered trademark of Jazz Pharmaceuticals, Inc.

© 2022 Jazz Pharmaceuticals, Inc. All rights reserved.

EMD  
SERONO

Pfizer



COMMITTED TO  
**UNDERSTANDING**  
**CANCER**

EMD Serono and Pfizer Canada—working together

© 2022 EMD Serono and Pfizer Canada ULC. All rights reserved.

EMD Serono, a Division of EMD Inc., Canada  
2695 North Sheridan Way, Suite 200  
Mississauga, ON L5K 2N6  
EMD Serono is a business of Merck KGaA, Darmstadt, Germany

Pfizer Canada ULC, Kirkland, QC H9J 2M5

CA-AVEBL-00086-EN





The work that you do matters.

Every day, you affect the lives of patients  
and their families. You all make a difference.

On behalf of GSK Oncology,

**thank you**

for all that you do

Ahead Together

**GSK**

# BRUKINSA STAYS ON, SO BTK STAYS OFF

Enroll your PrBRUKINSA® patients in the myBeiGene Patient Support Program. Visit [www.BRUKINSA.ca](http://www.BRUKINSA.ca) or call 1-833-234-4366.

24-hour inhibition of BTK was maintained at 100% in PBMCs and 94% to 100% in lymph nodes when taken at the recommended total daily dose of 320 mg. The clinical significance of 100% inhibition has not been established.<sup>1,2</sup>

**WM** TN & R/R WALDENSTRÖM'S  
MACROGLOBULINEMIA

**MCL** R/R MANTLE CELL  
LYMPHOMA

**MZL** R/R MARGINAL  
ZONE LYMPHOMA

BTK = Bruton's tyrosine kinase; PBMCs = peripheral blood mononuclear cells.

BRUKINSA (zanubrutinib) is indicated for the treatment of adult patients with Waldenström's macroglobulinemia (WM). It is also indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy and for the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy.

Consult the Product Monograph at [www.brukinsa.ca](http://www.brukinsa.ca) for important information on contraindications, warnings, precautions, adverse reactions, drug interactions and dosing.

**References:** 1. Brukinsa (zanubrutinib) Product Monograph. BeiGene Canada. February 17, 2022.

2. Tam CS, Trotman J, Opat S, et al. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. *Blood*. 2019;134(11):851-859.

BRUKINSA, BeiGene, and myBeiGene are registered trademarks owned by BeiGene, Ltd.

© BeiGene, Ltd. 2022 All Rights Reserved.

0922-BRU-PRC-067



## Introducing the Lapelga® (pegfilgrastim) Pre-Filled Autoinjector



Come by the Apobiologix exhibit booth or speak to your Apobiologix representative to learn more.





## **Congratulations to the nominees of the 2022 Boehringer Ingelheim Oncology Nurse of the Year Award!**

**Toutes nos félicitations aux candidat(e)s au prix  
Boehringer Ingelheim de l'infirmier(ère) de l'année pour 2022!**

**Joy Tarasuk, Bedford, NS  
Gail Larocque, Ottawa, ON**

**This award will be presented at the Awards of Excellence Ceremony at the Victoria Convention Centre in Victoria, British Columbia on Saturday, October 29, 2022 from 9:45am to 10:30am PST.**

**The ceremony will be live streamed on the CANO/ACIO Facebook page.**

**Congratulations and best wishes to all nominees.**

**Ce prix sera remis lors de la cérémonie de remise des prix d'excellence au Victoria Convention Centre à Victoria, en Colombie-Britannique, le samedi 29 octobre 2022 de 9h45 à 10h30 PST.**

**La cérémonie sera diffusée en direct sur la page Web Facebook de l'ACIO.**

**Félicitations et meilleurs vœux à tous les nominés.**

**CANO/ACIO gratefully acknowledges the generous support of Boehringer Ingelheim (Canada) for this award**

**L'ACIO/CANO tient à remercier Boehringer Ingelheim (Canada) du généreux soutien fourni envers ce prix.**

**LET'S COLLABORATE**  
ONCOLOGY FROM BOEHRINGER INGELHEIM



## THE CANO/ACIO AWARDS CEREMONY IS SCHEDULED FOR

**SATURDAY, OCTOBER 29, 2022**  
from 9:45am – 10:30am PST  
**Carson Hall Salon A at the  
Victoria Convention Centre**

The ceremony will be live streamed on  
the CANO/ACIO Facebook page.

At the ceremony we will recognize  
the extraordinary contributions of our  
members to their profession, their  
patients, and their community.

RECOGNIZING  
**CANO/ACIO  
STARS**

### THE FOLLOWING AWARDS WILL BE PRESENTED:

- ☆ Amgen Award for Innovation in Oncology Patient and Family Education
- ☆ BD Commitment to Safety Award
- ☆ Boehringer Ingelheim Nurse of the Year Award
- ☆ Pfizer Award of Excellence in Nursing Clinical Practice
- ☆ Pfizer Award of Excellence in Nursing Education
- ☆ Pfizer Award of Excellence in Nursing Leadership
- ☆ Pfizer Award of Excellence in Nursing Research
- ☆ Award for Excellence in Reviewing Peer Reviewed Manuscripts for CONJ
- ☆ Award for Best Manuscript in CONJ 2021 – 2022
- ☆ CANO Award of Distinction
- ☆ CANO Dr. Tracy Truant Memorial Scholarship NEW
- ☆ CANO Lifetime Achievement Award
- ☆ CANO Nursing Scholarship
- ☆ CANO Research Grant

### OUR TWO LECTURESHIP AWARDS WILL BE PRESENTED IN THE FOLLOWING SESSIONS:

#### HELENE HUDSON LECTURE AND AWARD PRESENTATION

Saturday, October 29, 2022 from  
2:00PM to 3:00PM PST

*Sponsored by Amgen*



#### CLINICAL LECTURESHIP AND AWARD PRESENTATION

Sunday, October 30, 2022 from 11:15AM to  
12:15PM PST

*Sponsored by Merck*



### THE FOLLOWING ABSTRACT AWARD WILL BE PRESENTED AT THE CLOSING CEREMONY:

Sunday, October 30, 2022 at 12:15PM – 12:45PM in Carson Hall Salon A.

### CANO/ACIO CHAPTER POSTER AWARDS!

Sponsored by the Alberta North, Alberta South, Manitoba, Quebec, Saskatchewan,  
Ontario-Champlain, and PEI Chapters.

**We wish to thank members for the leadership shown in nominating one of their colleagues for an award.  
And, we wish to thank the sponsors of the awards.**



Canadian Association of Nurses in Oncology  
Association canadienne des infirmières en oncologie

## LA CÉRÉMONIE DE REMISE DES PRIX DE L'ACIO/CANO AURA LIEU

**Samedi 29 octobre 2022 de 9h45 à 10h30 PST dans le Carson Hall Salon A du Victoria Convention Centre, Victoria, Colombie Britannique.**

La cérémonie sera diffusée en direct sur la page Web Facebook de l'ACIO.

La cérémonie nous permet de reconnaître la contribution hors pair de nos membres envers leur profession, leurs patients et la collectivité.

RECONNAISSANCE DES  
ÉTOILES DE  
L'ACIO/CANO

### NOUS Y PRÉSENTERONS LES PRIX SUIVANTS :

- ☆ Prix Amgen pour l'innovation dans l'enseignement aux patients en oncologie et à la famille
- ☆ Prix BD de l'engagement envers la sécurité
- ☆ Prix Boehringer Ingelheim de l'infirmière en oncologie de l'année
- ☆ Prix d'excellence Pfizer en pratique clinique infirmière
- ☆ Prix d'excellence Pfizer en Éducation infirmière
- ☆ Prix d'excellence Pfizer en Leadership infirmier
- ☆ Prix d'excellence Pfizer en Recherche infirmière
- ☆ Prix d'excellence pour la révision de manuscrits évalués par des pairs pour CONJ
- ☆ Prix du meilleur manuscrit dans CONJ 2021 - 2022
- ☆ Prix de distinction de l'ACIO
- ☆ Bourse d'études commémorative Dr. Tracy Truant de l'ACIO NOUVEAU
- ☆ Prix oeuvre de toute une vie de l'ACIO
- ☆ Bourse d'études en soins infirmiers de l'ACIO
- ☆ Subvention de recherche de l'ACIO

### NOS DEUX CONFÉRENCES DE REMISES DE PRIX SPÉCIAUX AURONT LIEU AUX HEURES ET DATES SUIVANTES :

#### PRÉSENTATION DU PRIX DE CONFÉRENCE À LA MÉMOIRE D'HELENE HUDSON

**Samedi 29 octobre 2022 de 14h00 à 15h00 PST**

*Commanditée par Merck Amgen*



#### CONFÉRENCE CLINIQUE ET REMISE DE PRIX

**Dimanche 30 octobre 2022 de 11h15 à 12h15 PST**

*Commanditée par Merck*



### LE PRIX ABSTRAIT SUIVANT SERA REMIS LORS DE LA CÉRÉMONIE DE CLÔTURE :

**DIMANCHE 30 OCTOBRE 2022 DE 12H15 À 12H45 DANS LE CARSON HALL SALON A.**

Prix de la meilleure affiche décerné par les sections de l'ACIO/CANO commanditée par les sections Alberta Nord, Alberta Sud, Manitoba, Québec, Saskatchewan, Ontario-Champlain et Île-du-Prince-Édouard.

**Nous tenons à remercier les personnes qui ont proposé la candidature d'un ou d'une de leurs collègues pour leur initiative. Nous souhaitons également remercier tous les commanditaires des prix !**




Canadian Association of Nurses in Oncology  
 Association canadienne des infirmières en oncologie

**CANO/ACIO Member Benefit Discount  
 Program Coming Soon!**

**Brands you like.  
 Deals you'll love.**

A free, members-only program  
 to save money at over 60  
 Canadian and international retailers.





CANO  
ACIO

Canadian Association of Nurses in Oncology  
Association canadienne des infirmières en oncologie

Le programme de rabais sur les avantages  
des membres de l'ACIO/CANO arrive bientôt !

# Des marques que vous aimez. Des rabais que vous adorez.

Un programme de rabais gratuit  
qui vous fait économiser  
chez plus de 60 partenaires réputées

CHOICE  
HOTELS CANADA®



L'ÉQUIPEUR


Reitmans



Penningtons

Bluenotes®

Lenovo



Canon /BOUTIQUE\*

BRICK.



clearly



ROGERS™



TELUS

Hilton  
HOTELS & RESORTS

brother

BAFFIN®  
NÉE DANS LE NORD. 1979.



# Contents

## Tables des matières

<b>SPONSOR AND EXHIBITOR LISTING</b> <b>LISTE DES COMMANDITAIRES ET EXPOSANTS</b>	<b>14</b>
<b>LETTER FROM THE PRESIDENT</b> <b>LETTRE DE LA PRÉSIDENTE</b>	<b>21</b>
<b>WELCOME TO THE 34<sup>TH</sup> ANNUAL CONFERENCE</b> <b>BIENVENUE À LA 34<sup>E</sup> CONFÉRENCE ANNUELLE</b>	<b>24</b>
<b>CONFERENCE OBJECTIVES</b> <b>OBJECTIFS DE LA CONFÉRENCE</b>	<b>24</b>
<b>GENERAL CONFERENCE INFORMATION</b> <b>INFORMATIONS SUR LA CONFÉRENCE</b>	<b>26</b>
<b>COMMITTEE LISTING</b> <b>LISTE DES MEMBRES DES COMITÉS</b>	<b>29</b>
<b>CONFERENCE FLOOR PLAN</b> <b>PLAN DU CENTRE DE CONFÉRENCES</b>	<b>32</b>
<b>EXHIBITOR LISTING</b> <b>LISTE DES EXPOSANTS</b>	<b>33</b>
<b>CONFERENCE PROGRAM-AT-A-GLANCE</b> <b>PROGRAMME DE LA CONFÉRENCE D'UN COUP</b>	<b>35</b>
<b>POSTER PRESENTATIONS</b> <b>SÉANCE D’AFFICHAGE</b>	<b>43</b>
<b>SPONSOR AND EXHIBITOR PROFILES</b> <b>PROFILS DE COMMANDITAIRES ET EXPOSANTS</b>	<b>44</b>



# Sponsor and Exhibitor Listing

## Liste des commanditaires et exposants

The 34<sup>th</sup> CANO/ACIO Annual Conference is made possible by the generous support of the following organizations:  
La 34<sup>ème</sup> conférence annuelle de l'ACIO/CANO est rendue possible grâce au généreux soutien des organisations suivantes:

### PLATINUM / PLATINE



### GOLD / OR



### SILVER / ARGENT



### BRONZE / BRONZE



### SYMPOSIA / SYMPOSIUM



### FOCUS GROUPS / PANEL DE DISCUSSION



### AWARD SPONSORS / COMMANDITAIRES DES RECOMPENSES



### EXHIBITORS / EXPOSANTS

AbbVie, Amgen, Apobiologix, Astellas, AstraZeneca Canada, B Braun, BC Cancer, BD, BeiGene, BioScript Solutions, Boiron, Bristol Myers Squibb, Canadian Cancer Society, Canadian Neuroendocrine Tumour Society (CNETS), Canadian Vascular Access Association, CNA, de Souza Institute, Elecrae, Eli Lilly, EMD Serono and Pfizer Canada, EUSA Pharma, FORUS Therapeutics, Gilead and Kite Oncology, GSK, GSK C19, ICU Medical, Incyte, Innovative OncoSolutions, Ipsen Biopharmaceuticals, Janssen, Jazz Pharmaceuticals, La Roche Posay, Leo Pharma, Leukemia and Lymphoma Society, Melanoma Canada, Merck, Merck Astra Zeneca, Nestle Health Sciences, Nipro Canada, Pfizer Canada, Sanofi, Save Your Skin Foundation, Seagen, Spectrum Therapeutics, Takeda, TEVA, Viatris



PRIME MINISTER • PREMIER MINISTRE

October 27–30, 2022

Dear Friends:

I am pleased to extend my warmest greetings to everyone attending the 34th Annual Conference of the Canadian Association of Nurses in Oncology (CANO).



As highly trained professionals with a unique set of knowledge and skills, oncology nurses play an integral role in the lives of patients living with a cancer diagnosis. It is fitting that the theme of this year's event, the first in-person gathering since the start of the COVID-19 pandemic, is "Together Again – Connection, Reflection, Celebration." I am certain that delegates will make the most of this opportunity to share experiences and expertise, celebrate past accomplishments and look to the future.

I would like to commend the members of CANO for advancing excellence in oncology nursing. You can take pride in knowing that your unwavering commitment to ensuring that cancer patients and their families have access to the highest standards of support and care, even during the most difficult of times, has touched countless lives. I would also like to thank the organizing committee for its hard work in putting together an informative and rewarding program for everyone involved.

Please accept my best wishes for an engaging and enriching experience.

Sincerely,

The Rt. Hon. Justin P. J. Trudeau, P.C., M.P.  
Prime Minister of Canada



PRIME MINISTER · PREMIER MINISTRE

Du 27 au 30 octobre 2022

Chers amis,

Je suis heureux de présenter mes salutations les plus chaleureuses à toutes les personnes qui participent à la 34<sup>e</sup> conférence annuelle de l'Association canadienne des infirmières en oncologie (ACIO).



À titre de professionnelles hautement qualifiées détenant un ensemble unique de connaissances et de compétences, les infirmières en oncologie jouent un rôle essentiel dans la vie des personnes qui reçoivent un diagnostic de cancer. Puisque la conférence de cette année sera la première à se tenir en personne depuis le début de la pandémie de COVID-19, son thème est tout à fait indiqué : « À nouveau réunis : connexions, réflexions, célébrations ». Je suis convaincu que les déléguées profiteront au maximum de l'occasion pour mettre en commun leurs expériences et leur expertise, souligner les réalisations passées et se tourner vers l'avenir.

Je tiens à féliciter l'ensemble des membres de l'ACIO pour leur promotion de l'excellence dans le domaine de l'oncologie. Vous pouvez tirer fierté de savoir que, par votre engagement indéfectible à fournir aux patients atteints du cancer et à leurs familles des soins et un soutien des plus dévoués, même pendant les périodes les plus sombres, vous avez touché d'innombrables vies. Je tiens également à remercier le comité organisateur de l'excellent travail qu'il a effectué pour établir un programme stimulant et informatif à l'intention des participantes et participants.

Je vous souhaite une expérience des plus captivantes et enrichissantes.

Cordialement,

Le très hon. Justin P. J. Trudeau, C.P., député  
Premier ministre du Canada



## A MESSAGE FROM PREMIER JOHN HORGAN

As Premier of the Province of British Columbia, I extend my warmest greetings to everyone attending the Canadian Association of Nurses in Oncology's 34th Annual Conference.

Working in oncology can be high stress at the best of times and serving on the frontlines of the pandemic has only increased that strain. The hours are long, the demands can be significant, and I know you have all sacrificed time with your loved ones to provide compassionate care. The incredible work you do is vital to ensuring the health and well-being of people across our country and your tireless efforts are an inspiration every day.

An event of this magnitude requires a great deal of energy and planning, and I would like to acknowledge the organizers for coordinating this conference at which attendees will learn the latest discoveries and innovations. To those traveling from across the country to Victoria, I offer a warm welcome. I hope you will enjoy your time here in our beautiful province.

Please accept my best wishes for an invigorating and successful conference!

  
HONOURABLE JOHN HORGAN  
PREMIER OF BRITISH COLUMBIA



## **Canadian Association of Nurses in Oncology Annual Conference Program Welcome Message**

A Message from Dr. Bonnie Henry, BC Provincial Health Officer

October 2022

Hello and Bonjour,

It is with heartfelt appreciation and gratitude that I welcome the members of the Canadian Association of Nurses in Oncology to Victoria for the “34th Annual CANO/ACIO Conference.”

This is a time to come together, to learn from each other, to celebrate achievements and recognize the tremendous contributions you have made to all Canadians in what has been the most incredibly challenging time.

I thank you for your unwavering commitment to provide the care that is needed to Canadians facing cancer and doing that with compassion and kindness. What you have done and continue to do each day makes a difference in the lives of families across this country.

I encourage you to celebrate your time together in Victoria and wish you the very best for your conference.

With Gratitude,

A handwritten signature in black ink, appearing to read "Bonnie Henry".

Bonnie Henry  
OBC, MD, MPH, FRCPC  
Provincial Health Officer



# Social Event

## Beautiful British Columbia: Reconnection and Rejuvenation

**Saturday, October 29, 2022**

**7:30pm at the**

**Fairmont Empress**

**Doors Open 6:30 • Dinner Served 7:30**

Join us for a beautiful evening at the iconic Victoria landmark, the Fairmont Empress. Starting the night in the luscious green Palm Court, we will have an evening of trivia, delicious food and dancing the night away in the elegant Crystal Ballroom.

**Ticket sales end Friday, October 21st.**

**Limited tickets available  
\$100 per ticket**

*Purchase your Tickets Here!*

*Thank you to the BC Chapter  
for sponsoring this Social Event*



**CANO  
ACIO**



# Soirée sociale

## Retrouvailles et revitalisation en Colombie- Britannique

**Samedi 29 octobre 2022,**

**19 h 30, Hôtel**

**Fairmont Empress**

**Ouverture des portes à 18h30,  
repas servi à 19h30**

Joignez-vous à nous pour une magnifique soirée à l'emblématique Fairmont Empress de Victoria. La soirée débutera au verdoyant Palm Court et se poursuivra dans l'élégante salle de réception Crystal, où vous pourrez converser, ravir vos papilles et danser toute la nuit.

**La vente des billets se termine le vendredi 21 octobre.**

**Billets disponibles  
en quantité limitée  
100 \$/billet**

*Achetez vos billets!*

*Merci à la section de la C.-B. de  
parrainer cette soirée sociale!*



**CANO  
ACIO**

# Letter from the President

## Lettre de la présidente

Dear Colleagues,

On behalf of the CANO/ACIO Board, it gives me great pleasure to welcome you, both in-person and virtually, to our 34<sup>th</sup> Annual Conference. This year's conference theme, **"Together Again: Connection, Reflection, Celebration"** exemplifies the excitement that comes with the prospect of being able to meet in person once again. For the past two years, we had to adapt to the limitations imposed by the pandemic and held our conference virtually. At the time of writing this letter, we are anticipating being able to hold our conference in person in Victoria in October. We will continue to monitor the ongoing COVID-19 pandemic situation and will ensure that we abide by all public health guidelines and recommendations.

While in-person conference attendance had been put on hold for the past couple of years, we know that there was no 'pause' button for cancer. We know that people continued to hear the words, *"you have cancer"* every day, that people continued to receive cancer treatment, and that people continued to experience loss due to cancer. The Canadian Partnership Against Cancer recently released a **report** on cancer in the COVID-19 era, highlighting the effects of the pandemic on the cancer care continuum. Disruptions to cancer prevention and screening services throughout the pandemic mean that we now face the potential that people have been living with undiagnosed and untreated cancer and that people may be diagnosed with later stage disease, ultimately leading to poor outcomes. Further, many Canadians who had been diagnosed with cancer before or during the pandemic experienced treatment delays or even cancellations. According to the Canadian Institute for Health Information, between March 2020 and June 2021, there were approximately **560,000 fewer** surgeries performed compared to pre-pandemic. Many of these were cancer surgeries. Public health restrictions, necessary in order to curb the spread of COVID-19, meant that customs and rituals typically observed when someone is dying or has died, were altered (such as the shift to virtual funerals) or abandoned altogether. The subsequent impact on grief and



Bonjour,

Au nom du conseil d'administration de l'ACIO/CANO, j'ai l'immense plaisir de vous souhaiter la bienvenue, en personne et en virtuel, à notre 34<sup>e</sup> congrès annuel. Le thème de cette année, **« À nouveau réunis : connexions, réflexions, célébrations »**, illustre bien la joie que nous avons de pouvoir à nouveau nous réunir en personne. Au cours des deux dernières années, nous avons dû nous adapter aux restrictions sanitaires et avons tenu notre congrès en mode virtuel. Au moment de rédiger cette lettre, nous espérons tenir notre congrès en personne à Victoria, en octobre. Nous continuerons à surveiller de près la situation actuelle, et veillerons à respecter toutes les directives et recommandations de la santé publique.

Malgré la pause temporaire des congrès en personne ces deux dernières années, nous savons que le cancer, lui, n'a pas pris de pause. Tous les jours, des gens obtiennent un diagnostic de cancer, reçoivent des traitements par suite de ce diagnostic ou vivent un deuil à cause de cette maladie. Le Partenariat canadien contre le cancer a récemment publié un rapport sur le cancer à l'ère de la COVID-19 pour mettre en évidence les effets de la pandémie sur le continuum des soins oncologiques. En somme, la pandémie a perturbé les services de prévention et de dépistage du cancer. Conséquence : des personnes sont peut-être atteintes d'un cancer non diagnostiqué et non traité, ou d'autres recevront un diagnostic à un stade avancé de la maladie et auront moins de chances de s'en remettre. De plus, pour bien des personnes ayant reçu un diagnostic avant ou pendant la pandémie, les traitements ont été retardés, voire annulés. Selon l'Institut canadien d'information sur la santé, entre mars 2020 et juin 2021, le nombre d'interventions chirurgicales réalisées a diminué d'environ 560 000 par rapport à la période pré-pandémique, et un grand nombre d'entre elles étaient liées au cancer. Les mesures de santé publique, nécessaires pour enrayer la propagation de la COVID-19, ont eu pour effet de modifier, et parfois même abolir, les rites et coutumes normalement observés lorsqu'une personne est mourante ou décédée (ex. le passage aux funérailles

bereavement remains unknown but we can anticipate challenges with disordered grief in the years to come. Given all of this, we know that people affected by cancer need us, now more than ever. At the same time, we are seeing extraordinary burnout and attrition in healthcare.

While there are no easy answers or quick fixes for these challenges, we hope that you will be energized and inspired by the learning, networking, and camaraderie that transpire during our conference. Further, we hope that you will be able to connect with one another, reflect on the challenges you've overcome over the past few years, and celebrate your accomplishments and contributions to cancer care. In addition to the incredible learning opportunities that the conference will afford, we invite you to partake in the various social and networking events as well.

This year's conference program is full of sessions that will address topics relevant for the practicing oncology nurse, educator, researcher, and leader. We are delighted to once again be able to offer a full workshop day on October 27. You will also see Board-sponsored workshops throughout the program; these workshops align with our new [Strategic Plan](#). We are excited to have two inspiring Keynote presentations, two lecture-ship presentations, three joint symposia, and numerous concurrent sessions. Topics that will be covered during the conference include (but are not limited to): health equity, global oncology, oncologic treatment, symptom management, palliative care, survivorship care, virtual care/telehealth, navigation, the impact of COVID-19 on cancer care, and medical assistance in dying. Conference content will be relevant for all nurses, from novice to expert.

We welcome everyone to attend our Annual General Meeting on Saturday, October 29 as the Board shares the work that has been done over the past year and looks ahead to 2023. The Annual General Meeting also serves as a forum for members to express their ideas and thoughts on how to move the Association forward. We need and value your participation and input. Be sure to attend the annual Awards of Excellence Ceremony, following the Annual General Meeting, to celebrate the tremendous work and achievements of your colleagues.

On behalf of the Board, I would like to thank the Conference Planning Steering Committee, the Local Plan-

virtuelles). On ignore encore les conséquences de ce phénomène sur les personnes endeuillées, mais il faut s'attendre à une augmentation des troubles du deuil dans les années à venir. Bref, les personnes touchées par le cancer ont plus que jamais besoin de nous. Mais, en même temps, nous observons un taux d'épuisement et d'attrition hors du commun dans le domaine de la santé.

Il n'existe pas de solution miracle, mais nous espérons que l'apprentissage, le réseautage et la camaraderie qui caractérisent habituellement nos congrès sauront vous motiver et vous inspirer. De plus, nous souhaitons voir des liens se tisser entre vous afin que vous puissiez faire le point sur les épreuves affrontées ces dernières années ainsi que souligner vos accomplissements et votre contribution à la lutte contre le cancer. Au-delà des formidables occasions d'apprentissage offertes par le congrès, vous pourrez également participer aux diverses activités sociales et de réseautage.

Le programme de cette année propose tout plein de séances sur des sujets pertinents pour les infirmières en oncologie, les infirmières pédagogues, les infirmières chercheuses et les responsables des soins infirmiers. Nous sommes ravis de pouvoir de nouveau offrir une journée complète d'ateliers le 27 octobre. Dans le programme, vous verrez également des ateliers parrainés par le conseil d'administration. Ils répondent aux objectifs de notre nouveau plan stratégique. Vous aurez la chance d'assister à deux séances plénières inspirantes, deux conférences, trois symposiums conjoints et plusieurs séances concurrentes. Les sujets abordés couvriront notamment l'équité en santé, l'oncologie dans le monde, le traitement du cancer, la prise en charge des symptômes, les soins palliatifs, les soins de survivance, les soins virtuels (télésanté), la navigation, les répercussions de la pandémie sur les soins du cancer, ainsi que l'aide médicale à mourir. Ce congrès est conçu pour tout le personnel infirmier, du novice à l'expert.

Vous êtes par ailleurs tous les bienvenus à notre assemblée générale annuelle, le samedi 29 octobre. Le conseil d'administration présentera le travail accompli dans les douze derniers mois, puis évoquera les perspectives pour l'année 2023. Cet événement sert également de tribune aux membres pour exprimer leurs idées et leurs réflexions sur l'avenir de l'Association. Votre participation et votre contribution sont précieuses. Soyez aussi des nôtres à la cérémonie annuelle de remise des prix d'excellence, qui se tiendra juste après l'assemblée générale annuelle pour récompenser le travail et les réussites remarquables de vos collègues.

Au nom du conseil, je tiens à remercier le comité organisateur du congrès, le comité de planification local, le comité de planification scientifique ainsi que le comité de reconnaissance de l'excellence pour leur travail acharné de cette année en vue du congrès. Merci à toute

ning Committee, the Scientific Program Committee, and the Recognition of Excellence Committee for their hard work throughout the year and leading up to the conference. Thanks to all at Malachite Management and especially Dana Cooper, Ernest Ho, Kimberly Morales, and Paul Fogerty for their support and efforts leading up to, during, and following the conference. Thank you to all of our conference sponsors, partners, and exhibitors. We are indebted to you for your support. Finally, thanks to all of our conference delegates and speakers. Without you, our conference would not be possible.

For those attending the conference in-person, we ask that you be kind to yourselves and others as you navigate being in close proximity with one another. Please be respectful that people may have varying degrees of comfort regarding in-person interactions. We will be abiding by local and provincial health restrictions and requirements and will update everyone accordingly. Please watch for conference announcements regarding the most up-to-date health and safety information.

In closing, I'd like to leave you with a quote by Haruki Marukami. The past few years have been a storm for all of us. The pandemic will leave an indelible mark and we will be irrevocably changed. We have immense opportunity to chart the course of how we emerge and heal from the storm, how we help others emerge from and heal from the storm, and how we prepare for the next storm.

*"And once the storm is over, you won't remember how you made it through, how you managed to survive. You won't even be sure whether the storm is really over. But one thing is certain. When you come out of the storm, you won't be the same person who walked in. That's what this storm's all about." – Haruki Murakami*

Wishing you all a wonderful conference,  
Bon congrès à tous et à toutes,

Sincerely,



Reanne Booker, PhD(c), MN, NP  
President, CANO/ACIO

l'équipe de Malachite Management, et en particulier à Dana Cooper, Ernest Ho, Kimberly Morales et Paul Fogerty pour leur soutien et leur contribution avant, pendant et après le congrès. Merci aussi à tous les commanditaires, partenaires et exposants; nous vous sommes redevables pour votre soutien. Enfin, merci à tous les participants et conférenciers. C'est grâce à vous que notre congrès peut avoir lieu.

Nous demandons aux personnes qui assisteront au congrès en personne de faire preuve de bienveillance envers elles-mêmes et envers les autres. Tous ne sont pas aussi à l'aise de voir des gens en personne; soyons compréhensifs. Sachez que nous respecterons les restrictions et exigences sanitaires régionales et provinciales, et nous vous tiendrons au courant de tout changement. Restez à l'affût de nos messages concernant les plus récentes directives de santé et sécurité.

En terminant, j'aimerais vous partager une citation de Haruki Murakami. Vous savez, nous venons de traverser une véritable tempête. La pandémie laissera une trace indélébile, rien ne sera plus comme avant. Cependant, nous disposons d'une chance unique : celle de trouver notre propre chemin dans la tempête, d'aider les autres à s'en sortir et à s'en remettre, et de nous préparer à la prochaine tourmente.

*« Une fois la tempête passée, tu te demanderas comment tu as fait pour la traverser, comment tu as fait pour survivre. Tu douteras, en fait, qu'elle soit vraiment terminée. Mais une chose est sûre : quand tu en sortiras, tu ne seras plus la même personne. Tel est le sens de cette tempête. »*  
– Haruki Murakami

# Welcome to the 34<sup>th</sup> Annual Conference

On behalf of the 2022 Local Planning Committee of the 34th annual CANO/ACIO conference, we warmly invite you to the province of British Columbia.

Beautiful BC is overflowing with natural abundance, from the Rocky Mountains on the east to the Pacific Ocean on the west. Located on the southern tip of Vancouver Island, Victoria is British Columbia's capital city and the oldest city in the Pacific Northwest. Experience this "garden city" by taking a stroll along the Inner Harbor, visiting one of the many historical sites, savoring superb local cuisine, enjoying an ocean adventure, or exploring the thriving arts and culture scene.

The Fairmont Empress Hotel looks out over the impressive Victoria Inner Harbor and will be the venue for your stay. This grand landmark has recently undergone a massive restoration while preserving the timelessness of the iconic Canadian Pacific Railway hotel history.

This year's theme "Together Again: Connection, Reflection, Celebration" highlights a return to welcoming attendees in-person to the annual conference. The challenges we have collectively faced during the pandemic have been considerable, so we look forward to sharing, learning and celebrating together again.

## Conference Objectives

- Provide a forum for oncology nurses to network and collaborate on current hot topics and future trends in oncology nursing practice
- To inspire nurses to celebrate the advances already achieved and to further advance oncology nursing through the dissemination of new and innovative practices and research findings
- Challenge nurses to examine their practice and drive innovations in care when they return to their settings with new ideas and enthusiasm for oncology patient care

# Bienvenue à la 34<sup>e</sup> conférence annuelle

Au nom du Comité de planification locale de 2022 pour la 34<sup>e</sup> conférence annuelle de l'ACIO/CANO, nous vous invitons chaleureusement en la province de la Colombie-Britannique

L'abondance naturelle de cette magnifique province s'étend des montagnes Rocheuses, du côté est, à l'océan Pacifique, du côté ouest. Située à la pointe sud de l'île de Vancouver, Victoria est la capitale de la Colombie-Britannique ainsi que la ville la plus ancienne du Nord-Ouest Pacifique. Elle est connue comme la « cité des jardins » et vous pourrez la découvrir en vous promenant le long de son arrière-port, en visitant l'un de ses nombreux lieux historiques, en dégustant sa cuisine gastronomique locale, en faisant une excursion en mer, ou en explorant sa scène culturelle et artistique dynamique.

L'hôtel Fairmont Empress surplombe le magnifique arrière-port et sera le lieu de votre séjour. Ce majestueux point de repère a récemment subi une rénovation importante, tout en conservant son caractère historique d'hôtel emblématique du Chemin de fer Canadien Pacifique.

Le thème de cette année, « À nouveau réunis : connexions, réflexions, célébrations », évoque le retour à un congrès en personne. Collectivement, nous avons surmonté des obstacles considérables pendant la pandémie. Nous avons hâte de célébrer, d'échanger et d'apprendre les uns des autres, en vrai!

## Objectifs de la conférence

- » Proposer une tribune au réseau des infirmières et infirmiers en oncologie où discuter en collaboration de sujets d'actualité brûlants ainsi que de tendances futures dans la pratique des soins infirmiers en oncologie
- » Inciter les infirmières et les infirmiers à promouvoir les progrès déjà réalisés et à améliorer les soins infirmiers en oncologie existants en disséminant des pratiques nouvelles et innovantes ainsi que les résultats de la recherche en oncologie.
- » Mettre les infirmières et les infirmiers au défi d'examiner leur pratique et de pousser les innovations dans le domaine des soins lorsqu'ils retourneront dans leur milieu, remplis de nouvelles idées et d'enthousiasme pour les soins aux patients en oncologie



# Passion for Patients

As a pioneer in antibody-drug conjugates (ADCs), Seagen has led the way in novel cancer therapeutics since 1998. Now, as a global company with a portfolio that includes a breakthrough oral medicine for patients with HER2+ metastatic breast cancer, we're committed more than ever to improving lives for people with cancer around the world.

[seagen.com](http://seagen.com)

Seagen and the Seagen Logo are the registered trademarks of Seagen Inc. ©2022 Seagen Inc. USM/COR/2021/0037



## 2022 CANO/ACIO Annual Conference

Amgen discovers, develops, manufactures, and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease, cardiovascular disease and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. For more information, visit [www.amgen.ca](http://www.amgen.ca)

©2022 Amgen Inc. All rights reserved.

[amgen.ca](http://amgen.ca)



## Trustworthy Nurse worthy

When it comes to biosimilars, you can trust in Teva Canada as a key partner.



teva | Canada



**Biosimilars.**  
Canadian Association of Nurses in Oncology  
Association canadienne des infirmières en oncologie

© 2022 Teva Canada Innovation G.P. - S.E.N.C.  
Montreal, Quebec, H2Z 1S8

## Viatrix Connects to the important pieces of Oncology patient care



ABEVMY® is a registered trademark of Mylan Institutional Inc.; licensed use by BGP Pharma ULC, a Viatrix company.  
FULPHILA® is a registered trademark of Mylan Institutional Inc., used under permission by BGP Pharma ULC, a Viatrix company.  
OGIVRI® is a registered trademark of Mylan Institutional Inc., used under permission by BGP Pharma ULC, a Viatrix company.  
VIATRIS and VIATRIS & Design are trademarks of Mylan Inc., used under permission by BGP Pharma ULC, a Viatrix company.  
©2022 Viatrix Inc. All rights reserved.  
MUL-2022-2020E - AL2022



# General Conference Information

## COVID-19 SAFETY PROTOCOLS

Health and safety measures will be in place as issued and/or recommended by provincial and local health authorities. We strongly recommend following Health Canada's guidelines for vaccination and mask wearing requirements. We strongly recommend wearing masks during the conference.

We will continue to monitor the health and safety guidelines mandated by the provincial and local health authorities, and provide up to date information to the delegates as we get closer to the conference.

## REGISTRATION HOURS

**Wednesday, October 26, 2022**

from 3:00pm - 6:00pm

**Thursday, October 27, 2022**

from 6:30am - 6:30pm

**Friday, October 28, 2022**

from 7:00am - 5:00pm

**Saturday, October 29, 2022**

from 7:00am - 5:30pm

**Sunday, October 30, 2022**

from 8:00am - 12:00pm

## ANNUAL GENERAL MEETING

The 2022 AGM will be held in-person on Saturday, October 29, 2022 at 8:30 - 9:30 AM PST.

Join us in Carson Hall Salon A at the Victoria Conference Centre, Victoria, BC.

Meeting materials are available here:

[www.cano-acio.ca/agm](http://www.cano-acio.ca/agm)

## SOCIAL EVENING

**Beautiful British Columbia: Reconnection and Rejuvenation**

**Saturday, October 29, 2022**

Join us for a beautiful evening at the iconic Victoria landmark, the Fairmont Empress. Starting the night in the lush green Palm Court, we will have an evening of trivia, delicious food and dancing the night away in the elegant Crystal Ballroom.

Thank you to the BC Chapter for sponsoring this Social Event.

## SPECIAL INTEREST GROUP MEETINGS

CANO/ACIO members can access any or all Special Interest Groups (SIGs). Currently there are SIGs in the following areas: adolescents & young adults, advanced practice nursing, complementary medicine, gynecology oncology, hematology/BMT, immuno-oncology, leadership, navigation, oncology & aging, palliative care, pediatric oncology, radiation, surgical oncology nursing and survivorship.

There will be a number of SIG meetings held at the conference to discuss current issues and trends and to support and promote collaboration across Canada. Anyone can join these meetings and if you are looking for more information, we encourage you to attend! You will find these meetings in the conference-at-a-glance.

## WIFI

1. Connect to the "VictoriaConference" WiFi signal on your device
2. Select "Complimentary"
3. Read and accept the terms and conditions
4. Select "Connect Me"
5. Enjoy complimentary WiFi access!

## GET THE APP SPONSORED BY PFIZER CANADA

Access the conference app to find the session schedule and descriptions, featured sponsors, speakers, and more!

1. Click on one of the following buttons.

Apple/iOS

Android

Web Version

2. Once downloaded, open the app. The app should open to the conference event. If not, search for "CANO/ACIO 2022 Annual Conference." You may be prompted to log in before downloading the event to the app. After entering your first name, last name, and email address, a verification code will be sent to your email and/or mobile number.

## SCENTS

Please note that this annual conference is a scent free environment. Please refrain from the use of perfumes or other strong scents during the conference.

## CONTINUING NURSING EDUCATION (CNE)

This event is approved for a maximum of 21 hours of accredited continuing nursing education by the Continuing Nursing Education (CNE) Office, Ingram School of Nursing, McGill University.

## GAMIFICATION

Join our game in the app to earn points and win prizes from our exclusive game prize sponsor, Look Good Feel Better!

In the Game Center in the app, you will see a variety of challenges you can participate in. When you click into a specific challenge, you will see the rules and how to collect points. The more challenges you participate in the more points you earn!

There are many ways to earn points including:

- Explore our exhibit hall and engage with sponsors
- Attend as many sessions as possible
- Earn additional points by attending Sponsored Symposia.

Top 10 point earners receive fabulous prizes from Look Good Feel Better



#1-3: Beauty Gift Basket that will be shipped directly to the winners

#4-10: Mini-Cosmetic Gift Basket

The game will end on Sunday, October 30th at 11:00 AM PDT. Winners will be announced at the Closing Remarks.

**Gamification Sponsor:**



## INFORMATION

For further information contact the conference secretariat: CANO/ACIO Management Office

1618 Station St, Vancouver, BC, V6A 1B6

Tel: 604.874.4322 Fax: 604.874.4378

Email: [info@cano-acio.ca](mailto:info@cano-acio.ca)

[www.cano-acio.ca](http://www.cano-acio.ca)



Canadian Association of Nurses in Oncology  
Association canadienne des infirmières en oncologie

# Informations sur la conférence

## COVID-19 PROTOCOLES DE SÉCURITÉ

Des mesures de santé et de sécurité seront mises en place selon les directives et/ou recommandations des autorités sanitaires provinciales et locales. Nous suggérons fortement de suivre les directives de Santé Canada en matière de vaccination et de port du masque. Nous suggérons fortement le port de masques pendant la conférence.

Nous continuerons à suivre les directives en matière de santé et de sécurité imposées par les autorités sanitaires provinciales et locales, et nous fournirons des informations actualisées aux délégués à l'approche de la conférence.

## HEURES D'INSCRIPTION

**Mercredi 26 octobre 2022** de 15h00 à 18h00

**Jeudi 27 octobre 2022** de 6h30 à 18h30

**Vendredi 28 octobre 2022** de 7h00 à 17h00

**Samedi 29 octobre 2022** de 7h00 à 17h30

**Dimanche 30 octobre 2022** de 8h00 à 12h00

## ASSEMBLÉE GÉNÉRALE ANNUELLE

L'AGA de 2022 se tiendra en personne le samedi 29 octobre 2022, de 8 h 30 à 9 h 30 HNP. Joignez-vous à nous dans le Carson Hall Salon A du Victoria Conference Centre, Victoria, BC.

Les documents de la réunion sont disponibles ici :

[www.cano-acio.ca/agm](http://www.cano-acio.ca/agm)

## SOIRÉE SOCIALE

**Retrouvailles et revitalisation en Colombie-Britannique**

**Samedi 29 octobre 2022**

Joignez-vous à nous pour une magnifique soirée à l'emblématique Fairmont Empress de Victoria. La soirée débutera au verdoyant Palm Court et se poursuivra dans l'élégante salle de réception Crystal, où vous pourrez converser, ravir vos papilles et danser toute la nuit.

Merci à la section de la C.-B. de parrainer cette soirée sociale!

## RÉUNIONS DE GROUPES D'INTÉRÊT SPÉCIAL

Les membres de l'ACIO/CANO peuvent accéder à n'importe lequel ou à tous les groupes d'intérêt spécial. Actuellement, il existe des groupes d'intérêt spécial dans les domaines suivants: adolescents et jeunes adultes, soins infirmiers en pratique avancée, médecine complémentaire, gynécologie oncologique, hématologie/TDM, immuno-oncologie, leadership, navigation, oncologie

et vieillissement, soins palliatifs, oncologie pédiatrique, radiothérapie, soins infirmiers en oncologie chirurgicale et survie.

Il y aura un certain nombre de réunions de groupes d'intérêt spécial tenues lors de la conférence pour discuter des enjeux et des tendances actuels et pour soutenir et promouvoir la collaboration au Canada. Quiconque peut se joindre à ces réunions et si vous cherchez plus d'informations, nous vous encourageons à participer!

Vous trouverez ces réunions dans le programme de la conférence en un coup d'œil.

## WIFI

1. Connectez-vous au signal WiFi "VictoriaConference" sur votre appareil électronique
2. Sélectionnez "Complimentary"
3. Lisez et acceptez les termes et conditions
4. Sélectionnez "Connect Me"
5. Profitez de l'accès WiFi gratuit !

## OBTENEZ L'APPLICATION COMMANDITÉE PAR PFIZER CANADA

Accédez à l'application de la conférence pour trouver l'horaire et la description des séances, les commanditaires vedettes, les conférenciers, et plus encore !

1. Cliquez sur l'un des boutons ci-dessous.

Apple/iOS

Android

Version Web

2. Une fois téléchargée, ouvrez l'application. L'application devrait s'ouvrir sur l'événement de la conférence. Si ce n'est pas le cas, recherchez "CANO/ACIO 2022 Annual Conference". Vous serez ensuite invité à vous connecter avant de télécharger l'événement sur l'application. Après avoir saisi votre prénom, votre nom et votre adresse email, un code de vérification sera envoyé à votre email et/ou à votre numéro de téléphone mobile.

## SENTEURS

Veuillez noter que cette conférence annuelle est un environnement sans parfum. Veuillez vous abstenir d'utiliser des parfums ou autres odeurs fortes pendant la conférence.

## FORMATION CONTINUE EN SCIENCES INFIRMIÈRES (FCSI)

Cet événement est approuvé pour un maximum de 21 heures de formation continue accréditées par le Bureau de la formation continue en sciences infirmières (FCSI) de l'École des sciences infirmières Ingram de l'Université McGill.

## GAMIFICATION

Participez à notre jeu dans l'application pour gagner des points et des prix offerts par notre sponsor exclusif, Look Good Feel Better !

Dans le Centre de Jeu de l'application, vous verrez une variété de défis auxquels vous pouvez participer. Lorsque vous cliquez sur un défi particulier, vous verrez les règles et comment accumuler des points. Plus vous participez à des défis, plus vous gagnez de points !

Il existe de nombreuses façons de gagner des points, notamment :

- Explorez notre salle d'exposition et engagez-vous auprès des sponsors
- Assister à autant de sessions que possible
- Gagnez des points supplémentaires en assistant aux symposiums sponsorisés, à l'assemblée générale annuelle, à la cérémonie de remise des prix et aux sessions de discours et de conférences

Les 10 premiers gagnants recevront des prix fabuleux de Look Good Feel Better.



n°1-3 : Paniercadeau beauté qui sera envoyé directement aux gagnants

n°4-10 : Mini panier cadeau cosmétique

Le jeu finira le dimanche, 30 octobre à 11 h 00 PDT. Les gagnants seront annoncés lors du discours de clôture.

Sponsor de la gamification :



## INFORMATION

Pour plus d'informations, veuillez contacter le Secrétariat de la Conférence :

Bureau de gestion de l'ACIO

1618 Station St, Vancouver, BC, V6A 1B6

Téléphone : 604.874.4322 Télécopieur : 604.874.4378

Courriel : info@cano-acio.ca

www.cano-acio.ca

# Committee Listing

## Liste des membres des comités

### CONFERENCE PLANNING STEERING COMMITTEE COMITÉ D'ORGANISATION DE LA CONFÉRENCE

Lorelei Newton, *PhD, RN, CPSC*  
Co-Chair

Simonne Simon, *MN, CON(C), CPSC*  
Co-Chair

Kathleen Hennessy, *RN, CON(C),  
CHPCN(C), 2022 LPC Co-Chair*

Tammy Pentney, *BScN, RN, 2022 LPC*  
Co-Chair

Andrea Knox, *RN, BSN, CON(C), 2022*  
SPC Chair

Scott Beck, *RN, BScN, 2022 SPC*  
Co-Chair

Jodi Hyman, *RN, BScN, CON(C), 2019*  
LPC Co-Chair

Rose Woloshyn, *RN, BN, 2019 LPC*  
Co-Chair

Michelle Rosentreter, *RN, BN, CON(C),  
2019 SPC Co-Chair*

Leslie Maskell, *BA, RN, BScN, Con(C),  
2023 LPC Co-Chair*

Heidi Thomas, *RN, BScN, CON(C), 2023*  
LPC Co-Chair

Cheryl Page, *RN, BSN, BSc, CON(C),  
BMTCN, 2023 SPC Co-Chair*

Janny Proba, *RN, BScN, MEd(C),  
CON(C), CHPCN(C), CVAA(C), 2023*  
SPC Co-Chair

### LOCAL PLANNING COMMITTEE COMITÉ DE PLANIFICATION LOCAL

Kathleen Hennessy, *RN, BScN,  
MSCHQ, CON(C), CHPCN(C), 2022 LPC*  
Co-Chair

Tammy Pentney, *RN, BSN, 2022 LPC*  
Co-Chair

Andrea Knox, *RN, BSN, CON(C), 2022*  
SPC Co-Chair

Scott Beck, *RN, BScN, 2022 SPC*  
Co-Chair

Jen Finck, *RN*

Samuel Hackett, *RN, BSN*

Senz Hamilton, *RN, BSN, CON(C)*

Michelle Lafreniere, *RN, BSN*

Tracey Varian, *RN, CON(C)*

Cloe Bailey Vignola Edwards, *RN,  
BSN, CON(C)*

### SCIENTIFIC PROGRAM COMMITTEE COMITÉ DU PROGRAMME SCIENTIFIQUE

Andrea Knox, *RN, BSN, CON(C), 2022*  
SPC Chair

Scott Beck, *RN, BScN, 2022 SPC*  
Co-Chair

Cheryl Page, *RN, BSN, BSc, CON(C),  
BMTCN, 2023 SPC Co-Chair*

Janny Proba, *RN, BScN, MEd(C),  
CON(C), CHPCN(C), CVAA(C), 2023*  
SPC Co-Chair

Manon Lemonde, *RN, PhD, CANO/  
ACIO Director-at-Large – Research*

### CANO BOARD OF DIRECTORS CONSEIL D'ADMINISTRATION DE L'ACIO

Reanne Booker, *RN, BScN, MN, NP*  
President / Présidente

Lorelei Newton, *PhD, RN*  
Vice-President / Vice présidente

Simonne Simon, *RN, MN, CON(C)*  
Treasurer / Trésorière

Kara Jamieson, *RN, MN, MEd, CON(C)*  
Director-at-Large – Communications  
/  
Conseillère générale, communications

Sarah Champ, *MN, RN, CON(C)*  
Director-at-Large – Education /  
Conseillère générale, éducation

Andrea Knox, *RN, BSN, MSN, CON(C)*  
Director-at-Large – External Relations  
/  
Conseillère générale, relation  
extérieures

Jodi Hyman, *RN, BScN, CON(C)*  
Director-at-Large – Membership /  
Conseillère générale, adhesion

Samantha Scime, *RN, MN, CON(C)*  
Director-at-Large, Professional  
Practice /  
Conseillère générale, pratique profe-  
sionnelle

Manon Lemonde, *RN, PhD*  
Director-at-Large – Research /  
Conseillère générale, recherché

Margaret Fitch, *RN, PhD*  
Canadian Oncology Nursing Journal  
Editor-in-Chief /  
Revue canadienne de soins infirmiers  
en oncologie,  
éditeur en chef

Catriona Buick, *PhD*  
Incoming Vice-President / Vice  
président entrant

Joy Tarasuk, *RN, BScN, MN, CHE,  
CON(C)*  
Incoming Director-at-Large – Com-  
munications /  
Conseillère générale entrant, commu-  
nications

### COUNCIL OF SPECIAL INTEREST GROUPS

Jodi Hyman, *RN, BScN, CON(C) (Chair)*  
Advanced Practice Nursing –  
Bonnie Leung,  
Andreane Chevrette

Gynecology Oncology – Michelle  
Ellwood,  
Trina Buick

Hematology / BMT – Kari Kolm,  
Kristine Leach

Immuno-Oncology – Marcia  
Flynn Post,  
Leslie Marvell

Leadership – Joy Tarasuk, Ruby  
Gidda

Navigation – Sarah Champ,  
Catherine Dixon

Oncology & Aging – Allison  
Wiens, Fay Strohschein

Palliative Care – Stephanie Lelond

Pediatric Oncology – Jill Bullock,  
Colette Longworth

Radiation – Amber Killam, Renata  
Benc

Surgical Oncology – Anita Long,  
Tracyann Machado

Survivorship – Carrie McDonald,  
Karine Bilodeau

## RECOGNITION OF EXCELLENCE COMMITTEE

Rana Jin, RN, MSN, CON(C) (Chair)  
Edith Pituskin, NP, PhD  
Heather Brander, RN, BScN,  
CHPCN(C), CON(C)  
Leah Lambert, RN, BScN  
Lorelei Newton, PhD, RN

## RESEARCH

Manon Lemonde, RN, PhD (Chair)  
Jill Bally, RN, PhD  
Jacqueline Galica, RN, MSc, PhD,  
CON(C)  
Kristen Haase, RN, PhD  
Leah Lambert, RN, PhD  
Virginia Lee, RN, PhD  
Marian Florence Luctkar-Flude, RN,  
BScN, MScN, PhD, CCSNE  
Christine Maheu, RN, PhD  
Samantha Mayo, RN, PhD  
Kylie Teggart, RN, BScN, CON(C)

## NATIONAL UNDERSERVED POPULATIONS WORKING GROUP

Andrea Knox, RN, BSN, MSN, CON(C)  
(Chair)  
Ali Hicks  
Allison Wiens, RN, BN  
Carolyn Roberts, RN  
Chantel Antone, RN, BScN  
Gabiella Wong Ken  
Tara Horrill, PhD, RN  
Jagbir Kaur, RN, BScN, MScN  
Joanne Crawford, RN, BScN, MScN,  
PhD  
Karina Frost  
Leah Lambert, RN, BScN  
Michelle Post, RN, MSN  
Morgan Stirling, MSc  
Murego Donat  
Samantha Scime, RN, MN, CON(C)  
Sarah Cleyrn, BScN, RN, MN  
Scott Beck, RN, BScN  
Tayreez Mushani, MHS, BScN, RN,  
CON(C), CHPCN(C)

## EDUCATION

Sarah Champ, RN, MN, CON(C) (Chair)  
Cynthia Heron, RN, BScN, CON(C)  
(Co-Chair)  
Laurie Ann Holmes, RN, BScN,  
CON(C), CHPCN(C)  
Heather Bussey, RN, BN, CON(C)  
Jodi Hyman, RN, BScN, CON(C)  
Kara Jamieson, RN, MN, MEd, CON(C)  
Lynn Kachuik, RN, BA, MS, CON(C),  
CHPCN(C)  
Terri McGrath, BScN, RN  
Natasha Olesen, RN, BScN  
Cheryl Page, RN, BSN, BSc, CON(C),  
BMTCN  
Shelley Somar, RN, MN, CON(C),  
CHPCN(C)  
Suganya Vadivelu, RN, BScN, MScN,  
CON(C), PGDHM  
Pat Yuzik, RN, MN, CON(C)

## COMMUNICATIONS

Kara Jamieson, RN, MN, MEd, CON(C)  
(Chair)  
Joy Tarasuk, RN, BScN, MN, CHE,  
CON(C) (Incoming Chair)  
April Hildebrand, RN, BScN (Social  
Media Ambassador)  
Catherine Fox, MN, RN, CON(C)  
Jodi Hyman, RN, BScN, CON(C)  
Zoe Ignacio, RN, BN, CON(C)  
Vanessa Pagtakhan, RN, BScN  
Hassan Zahreddine, RN, MN, OCN

## PROFESSIONAL PRACTICE

Samantha Scime, RN, MN, CON(C)  
(Chair)  
Jill Bullock, RN, BScN, MN CON(C)  
Audrey Chouinard, inf. M.Sc (CSIO)  
Sydney Farkas, RN, MN, CON(C)  
Marcia Flynn-Post, RN, BA, MHST,  
CON(C)  
Catherine Fox, MN, RN, CON(C)  
Terri Gray, BScN, CON(C)  
Lynne Jolicoeur, RN, MScN, CON(C)  
Kassie Nguyen, RN, BScN  
Cheryl Page, RN, BSN, BSc, CON(C),  
BMTCN  
Jennifer Stephens, MA, PhD, RN, OCN  
Andrea Wong, RN, BScN, CON(C)

## Chapter Executives

### BC CHAPTER

Andrea Knox, *President, Membership & Communications Chair*  
Michelle LaFreniere, *Past President*  
Suzanne Daniel, *Vice President*  
Senz Hamilton, *Treasurer*

### NORTHWEST TERRITORIES CHAPTER

Catherine Dixon, *President*  
Julie Jones, *Vice President/Treasurer*  
June Bartlett, *Secretary*

### ALBERTA NORTH CHAPTER

Jaymi Rumsey, *President*  
Vanessa Pagtakhan, *Vice-President*  
Bonnie Harrison, *Treasurer*  
Mike Harding, *Secretary*  
Sheldon Wong, *Social Media Director*

### ALBERTA SOUTH CHAPTER

Rachelle Wilson, *President*  
Tevi Nergaard, *Vice-President*  
France Singleton, *Vice-President*  
Tammy Patel, *Past President*  
Michael Stroccl, *Treasurer*  
Brooke ter Denge, *Treasurer*  
Sarah Quinn, *Industry Liaison*  
Gurpreet Sidhu, *Student Representative & Social Media Coordinator*

### SASKATCHEWAN CHAPTER

Joyce Allan, *President*  
Shauna Houshmand, *Vice-President / Past President*  
Meighan Kozlowski, *Treasurer*  
Patricia Yuzik, *Secretary*

### MANITOBA CHAPTER

Jodi Hyman, *President*  
Michelle Rosentreter, *Vice-President*  
Kathy Ramesar, *Treasurer*  
Zoe Ignacio, *Secretary, Scholarship's Chair*  
Jordana Jones, *Editor & Publisher of the Oncologic*

### ONTARIO-HORSESHOE CHAPTER

Heidi Thomas, *President*  
Cheryl Page, *Vice President*  
Janny Proba, *Secretary*  
Leslie Maskell, *Treasurer*

### ONTARIO-GREATER TORONTO CHAPTER

Shawne Gray, *President*  
Philiz Goh, *Past President*  
Gayatre Maharaj, *Director of Communications*  
Suzanne Scotland, *Director of Recruiting and Retention*  
Susie Monginot, *Director at Large*  
Sonali Kirshenbaum, *Newsletter Editor In Chief*  
Kassie Nguyen, *Events Coordinator*  
Taaha Ijaz, *Student Representative*

### ONTARIO-CHAMPLAIN CHAPTER

Philip Nguyens, *President*  
Amber Killam, *Vice-President*  
Vicky Samuel, *Treasurer*  
Alda Kiss, *Secretary*

### QUEBEC CHAPTER

Maryse Carignan, *Présidente*  
Marika Swidzinski, *Conseillère - Liaison CANO/ACIO*  
Linda Hershon, *Vice-Présidente*  
Alexis Parent, *Trésorière*  
Billy Vinette, *Secrétaire et co-organisateur du Séminaire Annuelle*  
Marie-Ève Belanger, *Éducation*  
Annie Jean, *Site web, Facebook et Communications*  
Maude Hébert, *Prix d'excellence et bourses*  
Gabrielle Chartier, *Co-organisatrice du Séminaire Annuelle et Site web*  
Audrey Chouinard, *Liaison formation universitaire et groupe d'étude interétablissement pour la certification de l' Association des infirmières et infirmiers du Canada*

### NEW BRUNSWICK-MONCTON CHAPTER

Carolyn DeVito, *President*  
Jenna McDougall, *Vice-President*  
Laura Booth, *Treasurer*  
Andrea Rose, *Secretary*

### PEI CHAPTER

Lisa Bishop, *President*  
Kara McQuid-Duffy, *Vice President*  
Amy Smith, *Treasurer*  
Janet Sharpe, *Secretary*

### NOVA SCOTIA CHAPTER

Kara Jamieson, *President*  
Heather Brander, *Vice President*  
Jeannie Kennedy, *Treasurer*  
Margaret Woods, *Secretary*


### NEWFOUND & LABRADOR CHAPTER

Bernadine O'Leary, *Chapter Contact*  
Tracey King, *Chapter Contact*


# Conference Floor Plan

## Plan du centre de conférences

### LEVEL 1




### LEVEL 2



# Exhibitor Listing / liste des exposants

E-POSTER  
STATION #1/  
POSTE DES  
AFFICHES N° 1

E-POSTER  
STATION #2/  
POSTE DES  
AFFICHES N° 2



EXHIBITORS / EXPOSANTS	#	EXHIBITORS / EXPOSANTS	#	EXHIBITORS / EXPOSANTS	#
AbbVie	20	de Souza Institute	48	Leo Pharma	16
Amgen	18	Elecræe	34	Leukemia and Lymphoma Society	30
Apobiologix	19	Eli Lilly	50	Melanoma Canada	31
Astellas	23	EMD Serono and Pfizer Canada	22	Merck	44
AstraZeneca Canada	26	EUSA Pharma	17	Merck AstraZeneca	24
B Braun	28	FORUS Therapeutics	43	Nestle Health Sciences	53
BD	32	Gilead and Kite Oncology	21	Nipro Canada	15
BeiGene	6	GSK	3	Pfizer Canada	1
BioScript Solutions	37	GSK C19	46	PHSA	35
Boiron	40	ICU Medical	49	Sanofi	14
Bristol Myers Squibb	7	Incyte	33	Save Your Skin Foundation	36
Canadian Cancer Society	41	Innovative OncoSolutions	52	Seagen	45
Canadian Neuroendocrine Tumour Society (CNETS)	29	Ipsen Biopharmaceuticals	38	Spectrum Therapeutics	54
Canadian Vascular Access Association	42	Janssen	4	Takeda	51
CNA	47	Jazz Pharmaceuticals	39	TEVA	56
		La Roche Posay	5	Viatrix	55



# Conference Program-at-a-Glance

## Programme de la conférence d'un coup

WEDNESDAY, OCTOBER 26, 2022

MERCREDI 26 OCTOBRE 2022

3:00pm – 6:00pm	Registration / Inscription	Registration Area
3:00pm – 6:00pm	Speaker Services / Bureau des services aux conférenciers	Victoria

DAY ONE: CONFERENCE WORKSHOP DAY: THURSDAY, OCTOBER 27, 2022 /

JOUR UN : JOURNÉE D'ATELIER DE LA CONFÉRENCE : JEUDI 27 OCTOBRE 2022

6:30am – 6:30pm	Registration / Inscription	Registration Area
6:30am – 6:30pm	Speaker Services / Bureau des services aux conférenciers	Victoria

7:00am – 8:15am **Pfizer Breakfast Symposium / Déjeuner éducatif Pfizer**  
 The Nurses' View: Targeted Therapy for BRAF-Mutated Metastatic Colorectal Cancer and Melanoma  
 Dr. Vanessa Bernstein, Mia Dodge, Dr. Jeremy Ho, Leslie Maskell  
 Carson Hall Salon A

8:15am – 11:45am	<b>Workshop / Atelier W-01-A</b> <i>Esquimalt</i> 📖 Optimizing Diagnosis in Canadian Cancer Care: Findings, Recommendations, Next Steps, and Implications for Key Stakeholders including Oncology Nurses Marianne Gagnon, Martin Dawes, Michael Smylie, Kathy Barnard	<b>Workshop / Atelier W-02-A</b> <i>Oak Bay 2</i> 📖 Health Equity and Equity-Oriented Cancer Care: What It Is, and Why It Matters to Oncology Nursing Tara Horrill, Jagbir Kaur, Leah Lambert, Scott Beck	<b>Workshop / Atelier W-03-A</b> <i>Oak Bay 1</i> 📖 Hematology Nursing Workshop Jennifer Wiernikowski, Donalda MacDonald, Komal Patel, Gayatre Maharaj, Jiahui Wong	<b>Workshop / Atelier W-04-A</b> <i>Saanich 1+2</i> 📖 Excellence in Oncology Nursing Leadership – Nursing Leadership in Times of Crisis Ruby Gidda, Joy Tarasuk	<b>Workshop / Atelier W-05-A</b> <i>Sidney</i> 📖 <b>CVAA</b> 📖 I'd Tap That: Am I Here In Vein? Janny Proba	<b>Workshop / Atelier W-06-A</b> <i>Colwood 1+2</i> 📖 International Partnerships in Cancer Care – Cultural Bridging for Oncology Nurses Reanne Booker, Savitri Singh-Carlson, Amanda Choffet, Marg Fitch, Andrea Knox, Lewelyn Rigor, Lori Spies
------------------	---	---	---	---	--	--

11:45am – 1:15pm **AstraZeneca Lunch Symposium / Dîner éducatif AstraZeneca**  
 Perspectives of a HER2+ metastatic Breast Cancer Patient  
 Dr. Nancy Nixon  
 Carson Hall Salon A

1:30pm – 5:00pm	<b>Workshop / Atelier W-01-B</b> <i>Esquimalt</i> 1:30pm – 3:15pm 📖 Integration of Oncofertility Screening, Assessment and Supports for Adolescent and Young Adult (AYA) Cancer Patients: A Workshop for Oncology Nurses Claire Link, Andrea Delure, April Hildebrand, Linda Watson, Lindsay Chmielewski, Sarah Thompson	<b>Workshop / Atelier W-02-B</b> <i>Oak Bay 2</i> 1:30pm – 3:15pm 📖 Leading the Way: Increasing Nurses' Contributions to Genomics and Precision Health Care Lindsay Carlsson, Jacqueline Limoges, Rebecca Puddester	<b>Workshop / Atelier W-03-B</b> <i>Oak Bay 1</i> 📖 Oncologic Emergencies Workshop Komal Patel, Donalda MacDonald, Jennifer Wiernikowski, Gayatre Maharaj, Jiahui Wong	<b>Workshop / Atelier W-05-B</b> <i>Sidney</i> 📖 <b>CINA</b> 📖 Canadian Indigenous Cancer Strategy Across the Spectrum Lea Bill, Dr. Angeline Letendre	<b>Workshop / Atelier W-06-B</b> <i>Colwood 1+2</i> 1:30pm – 3:15pm 📖 Reflecting & Connecting: Optimizing Sexual Health & Intimacy After a Cancer Diagnosis Reanne Booker
-----------------	---	--	--	---	--



**DAY ONE: CONFERENCE WORKSHOP DAY: THURSDAY, OCTOBER 27, 2022 /  
JOUR UN : JOURNÉE D'ATELIER DE LA CONFÉRENCE : JEUDI 27 OCTOBRE 2022**

	<p><b>W-01-C</b> <i>Esquimalt</i> 3:30pm – 5:00pm ✍️ <b>Optimizing Care – Introducing a Toolkit to Inform Nursing Assessment and Intervention for Age Related Changes in Older Adults with Cancer</b> <i>Allison Wiens, Fay Strohschein</i></p>	<p><b>W-06-C</b> <i>Colwood 1+2</i> 3:30pm – 5:00pm 📖 <b>Writing for Peer-Reviewed Journals: Getting Started</b> <i>Margaret Fitch and the CONJ Editorial Committee</i></p>						
5:15pm – 6:15pm	<p><b>CANO and Canadian Cancer Society Joint Symposium / Symposium conjoint de l'ACIO et de la Société canadienne du cancer   Facebook Live</b> Building Bridges Between Clinic and Community: Supporting Patients and Caregivers Living in Rural and Remote Canada <i>Laura Burnett, Reanne Booker</i></p>							
6:15pm – 8:00pm	<p><b>Welcome Reception / Réception de bienvenue</b></p>							
7:30pm – 9:30pm	<p><b>Focus Groups / Panels de discussion</b></p> <table border="1"> <tr> <td> <p><b>AstraZeneca Ad Board Meeting / Réunion du conseil d'administration AstraZeneca</b> <i>Saanich 1+2</i></p> </td> <td> <p><b>Leukemia and Lymphoma Society of Canada Focus Group / Panels de discussion La Société de leucémie et lymphome du Canada</b> The Leukemia and Lymphoma Society of Canada partnering with you to support the blood cancer community <i>Nadive Prevost</i> <i>Oak Bay 1</i></p> </td> <td> <p><b>Pfizer Focus Group / Panels de discussion Pfizer</b> <i>Oak Bay 2</i></p> </td> <td> <p><b>Jazz Pharmaceuticals Focus Group / Panels de discussion Jazz Pharmaceuticals</b> <i>Esquimalt</i></p> </td> <td> <p><b>Merck AstraZeneca Focus Group / Panels de discussion Merck AstraZeneca</b> Understanding the role of Oncology Nurses in genetic testing &amp; PARP management <i>Sidney</i></p> </td> <td> <p><b>Gilead Ad Board</b> Gilead Advisory Board for Metastatic Triple-Negative Breast Cancer <i>Colwood 1+2</i></p> </td> </tr> </table>		<p><b>AstraZeneca Ad Board Meeting / Réunion du conseil d'administration AstraZeneca</b> <i>Saanich 1+2</i></p>	<p><b>Leukemia and Lymphoma Society of Canada Focus Group / Panels de discussion La Société de leucémie et lymphome du Canada</b> The Leukemia and Lymphoma Society of Canada partnering with you to support the blood cancer community <i>Nadive Prevost</i> <i>Oak Bay 1</i></p>	<p><b>Pfizer Focus Group / Panels de discussion Pfizer</b> <i>Oak Bay 2</i></p>	<p><b>Jazz Pharmaceuticals Focus Group / Panels de discussion Jazz Pharmaceuticals</b> <i>Esquimalt</i></p>	<p><b>Merck AstraZeneca Focus Group / Panels de discussion Merck AstraZeneca</b> Understanding the role of Oncology Nurses in genetic testing &amp; PARP management <i>Sidney</i></p>	<p><b>Gilead Ad Board</b> Gilead Advisory Board for Metastatic Triple-Negative Breast Cancer <i>Colwood 1+2</i></p>
<p><b>AstraZeneca Ad Board Meeting / Réunion du conseil d'administration AstraZeneca</b> <i>Saanich 1+2</i></p>	<p><b>Leukemia and Lymphoma Society of Canada Focus Group / Panels de discussion La Société de leucémie et lymphome du Canada</b> The Leukemia and Lymphoma Society of Canada partnering with you to support the blood cancer community <i>Nadive Prevost</i> <i>Oak Bay 1</i></p>	<p><b>Pfizer Focus Group / Panels de discussion Pfizer</b> <i>Oak Bay 2</i></p>	<p><b>Jazz Pharmaceuticals Focus Group / Panels de discussion Jazz Pharmaceuticals</b> <i>Esquimalt</i></p>	<p><b>Merck AstraZeneca Focus Group / Panels de discussion Merck AstraZeneca</b> Understanding the role of Oncology Nurses in genetic testing &amp; PARP management <i>Sidney</i></p>	<p><b>Gilead Ad Board</b> Gilead Advisory Board for Metastatic Triple-Negative Breast Cancer <i>Colwood 1+2</i></p>			

**DAY TWO: FRIDAY, OCTOBER 28, 2022  
JOUR DEUX : VENDREDI, 28 OCTOBRE 2022**

6:30am – 7:00am	<p><b>Morning Rejuvenation Yoga Session / Séance de yoga de rajeunissement du matin</b> Begin your day opening and preparing your body to receive knowledge. Join us for an instructor-led yoga session Commencez votre journée en ouvrant et en préparant votre corps à recevoir la connaissance. Rejoignez-nous pour une séance de yoga dirigée par un instructeur.</p>	<i>Pre-Function 2B</i>
7:00am – 5:00pm	Registration / Inscription	<i>Registration Area</i>
7:00am – 5:00pm	Speaker Services / Bureau des services aux conférenciers	<i>Victoria</i>
7:00am – 5:00pm	<p><b>Calm &amp; Quiet Lounge / Salon Calme &amp; Tranquille</b> A space to recentre, regroup and reflect / Un espace pour se recentrer, se regrouper et réfléchir</p>	<i>Metchosin</i>
7:00am – 8:15am	<p><b>GSK Canada Breakfast Symposium / Déjeuner éducatif GSK Canada</b> Managing patients on PARPi for OC: Cases from the community <i>Heidi Thomas</i></p>	<i>Carson Hall Salon A</i>
8:30am – 9:15am	<p><b>Opening Ceremony / Cérémonie d'ouverture   Facebook Live</b></p>	<i>Carson Hall Salon A</i>

**DAY TWO: FRIDAY, OCTOBER 28, 2022**  
**JOUR DEUX : VENDREDI, 28 OCTOBRE 2022**

9:15am – 10:15am <b>Keynote Address I / Conférence plénière I   Facebook Live</b> <b>INDIGENOUS CANCER CARE IN BC / LES SOINS ONCOLOGIQUES AUX AUTOCHTONES EN COLOMBIE-BRITANNIQUE</b> <b>Warren Clarmont</b>							Carson Hall Salon A
10:00am – 4:00pm Exhibit Hall Open / Ouverture de la salle d'exposition							Carson Hall Salon B+C
10:15am – 10:45am Health Break & Poster Presentations Group A / Pause santé et présentations d'affiches Groupe A							Carson Hall Salon B+C
<b>Concurrent Session:</b> 10:45am – 12:05pm A: 10:45am – 11:05am	<b>Concurrent Session / Atelier simultané</b> I-1 <i>Lecture Theatre</i> <b>Addressing Inequities in Oncology</b> ✔ A - Connection, Reflection and Celebration: Coming Together to Develop a Sexual and Gender Diversity in Cancer Care (SGDC) Program <i>Samantha Scime, Nazlin Jivraj</i>	<b>Concurrent Session / Atelier simultané</b> I-2 <i>Esquimalt</i> <b>Symptom Management</b> 🔥 A - Understanding Factors Influencing Canadian Oncology Nurses' Discussing Cannabis Use with Patients Experiencing Chemotherapy – induced Nausea <i>Tianhao Xiao</i>	<b>Workshop / Atelier</b> I-3 <i>Oak Bay 1+2</i> 📖 Enhancing Competency-based Learning in Systemic Therapy Administration Using a Standardized and Blended Online and Workshop Model <i>Jiahui Wong, Donalda MacDonald, Gayatre Maharaj, Jennifer Wiernikowski, Shankavi Vigneswaran</i>	<b>Concurrent Session / Atelier simultané</b> I-4 <i>Saanich 1+2</i> <b>Leveraging Technology</b> 🔥 A - Designing a Proof-of-Concept of an App to Coordinate Nurse-Provided Respite Care Services for Families Coping with Palliative <i>Aimee Castro</i>	<b>Concurrent Session / Atelier simultané</b> I-5 <i>Sidney</i> <b>Specialized Oncology Practice</b> 👂 A - Critical Shortages of Chemotherapy-Certified Nurses and Practice Challenges: Management of HDMTX Toxicities <i>Preetal Makan, Kassie Nguyen</i>	<b>Concurrent Session / Atelier simultané</b> I-6 <i>Colwood 1+2</i> <b>Role Optimization</b> ✔ A - Care Coordination: Optimizing the Scope and Role of Oncology Nurses to Meet the Individual Needs of Patients and Families within Cancer Care <i>Joy Bunsko, Kornelia Filipowski, Theresa Zapach</i>	
B: 11:05am – 11:25am	🔥 B - Examining the Unmet Needs of Panjabi-Sikh Patients During the Treatment Phase of Cancer Care <i>Jagbir Kaur, Fuchsia Howard, Leah Lambert, Sally Thorne, Satwinder Bains</i>	👂 B - Utilizing Patient Reported Outcomes (PROs) and Toxicity Assessment to Improve Efficiencies in Nursing Practicing: A Stepped Assessment Approach <i>Claire Link, Andrea Delure, April Hildebrand, Linda Watson, Lindsay Chmielewski, Louise Smith</i>		✔ B - Implementing Virtual Care Overnight: A Pilot Project Evaluating the Available Technologies for Virtual Patient Care <i>Colleen Graham</i>	👂 B - Common Symptom Clusters in Advanced Cancers <i>Stephanie Lelond</i>	✔ B - Connecting Resources and Fostering Partnerships to Build Capacity in the Outpatient Systemic Therapy Setting <i>Yvonne Davidson, Jesse Haas</i>	
C: 11:25am – 11:45am	✔ C - A Time for Reflection: Exploring the Unique Perceptions and Experiences of Black Patients with Mental Health Issues at End-of-Life <i>Corsita Garraway</i>	✂ C - Chewing the Fat: A Nurse's Guide to Understanding the Role of Adipose Tissue in Cancer Cachexia <i>Susan McClement</i>		👂 C - Connecting the "Bots": Leveraging Digital Technology to Better Serve our Patients and their Families <i>Joy Bunsko, Justine Sanders, Megan Crosby</i>	👂 C - Early Intervention of Harm Reduction for Hematology Patients with Substance Use Disorder <i>Mei Wang, Karen Szeto</i>	📖 C - Enhancing Practice for Oncology Nurses - Systemic Therapy Initial and Continuing Competency Education <i>Suganya Vadivelu, Cheryl Page, Laura Sinke</i>	
D: 11:45am – 12:05pm	🔥 D - Digital Information Needs & eHealth Literacy of Older Adults with Cancer <i>Lorelei Newton, Claire Fullerton, Helen Monkman</i>	👂 D - Streamlining Care: A Nurse-Led Inter-Hospital Febrile Neutropenia Project <i>Luisa Luciani Castiglia, Jeff Mangerpan</i>		📖 D - Transitioning Breast Cancer Surgery Education Online: A COVID-19 Quality Improvement Project <i>Jayne Grigorovich, Sarah Rotstein</i>	👂 D - Surgical Insertion of Tunneled Drainage Catheters: Implications for Care in Palliative Patients <i>Janny Proba</i>	📖 D - The Pan-Canadian Oncology Symptom Triage and Remote Support (COSTaRS) Online Tutorial: Retrospective Pre-/Post-test Study <i>Dawn Stacey, Andra Davis, Lynne Jolicoeur, Meg Carley</i>	

**DAY TWO: FRIDAY, OCTOBER 28, 2022**  
**JOUR DEUX : VENDREDI, 28 OCTOBRE 2022**

12:15pm – 1:45pm <b>EMD Serono and Pfizer Canada Lunch Symposium / Dîner éducatif EMD Serono et Pfizer Canada</b> UC NOW: A multidisciplinary approach to optimizing the use of maintenance immunotherapy in the management of locally advanced or metastatic urothelial carcinoma <i>Nikita Ivanov, Dr. Bernhard Eigl, Glenn Myers, Michelle Forman</i> <span style="float: right;">Carson Hall Salon A</span>							
<b>Concurrent Session:</b> <b>2:00pm – 3:20pm</b> <b>A:</b> 2:00pm – 2:40pm  <b>B:</b> 2:40pm – 3:00pm  <b>C:</b> 3:00pm – 3:20pm	<b>Concurrent Session / Atelier simultané</b> <b>II-1</b> <i>Lecture Theatre</i> <b>Pediatric Oncology</b> <b>A</b> - Medical Assistance in Dying for Mature Minors <i>Shingirayi Priscilla Chataika-Smyth</i>	<b>Concurrent Session / Atelier simultané</b> <b>II-2</b> <i>Esquimalt</i> <b>Continuum de soins</b> <b>French</b> <b>A</b> - Nursing Leadership in the Pre-diagnostic Phase of Care of Suspected Patients With Lung Cancer (Bilingual Session) <i>Sonia Joannette, Sophie Burette</i> <b>B</b> - Une théorisation ancrée sur l'évolution des perceptions du rôle des infirmières lors du soin de l'aide médicale à mourir <i>Maude Hebert, Myriam Asri</i>	<b>Workshop / Atelier</b> <b>II-3</b> <i>Oak Bay 1+2</i> <b>Cancer and Social Justice:</b> What's Advocacy Got To Do With It? <i>Scott Beck, Sarah Cleyn, Joanne Crawford, Andrea Knox, Carolyn Roberts, Morgan Stirling, Allison Wiens, Gabriella Wong Ken</i>	<b>Concurrent Session / Atelier simultané</b> <b>II-4</b> <i>Saanich 1+2</i> <b>Patient Education</b> <b>A</b> - Educating Patients on Immune Checkpoint Inhibitors: Ensuring a Patient Centered Learning Approach <i>Kristyn Cole</i> <b>B</b> - Unveil the Experiential Knowledge Acquired by Healthcare Professionals to Accompany People Touched by Cancer: Educational Perspectives <i>Karine Bilodeau, Asma Fadhlou, Cynthia Henriksen, Lynda Piché</i> <b>C</b> - ELSKA A Simple Patient Reported Outcome and Teaching Tool Developed by an Old Bedside Nurse <i>Janet Funk</i>	<b>Concurrent Session / Atelier simultané</b> <b>II-5</b> <i>Si dney</i> <b>Clinical Service Innovation</b> <b>A</b> - Urgent CancerCare Clinic - An Introduction <i>Christine Eisma</i> <b>B</b> - A Smart Move: The Development and Implementation of a Nurse-Led, Non-Hazardous Infusion Clinic <i>Kathy Carothers, Angela Boudreau, Kirsty Wield</i> <b>C</b> - An Integrative Review of Cardio-Oncology Interdisciplinary Clinics and the Role for Nursing <i>Tara Reber</i>	<b>Concurrent Session / Atelier simultané</b> <b>II-6</b> <i>Colwood 1+2</i> <b>Early Palliative Care</b> <b>A</b> - Early Integration of Palliative Care <i>Jean Ann Ryan</i> 2:40 pm – 3:20pm <b>B</b> - Automatic Referrals to Palliative Care for Newly Diagnosed Stage IV Lung Cancer Patients: Connecting Research and Clinical Practice <i>Vanessa Slobogian</i>	
	3:30pm – 4:00pm Health Break & Poster Presentations Group B / Pause santé et présentations d'affiches Groupe B <span style="float: right;">Carson Hall Salon B+C</span>						
	4:00pm – 5:00pm <b>Annual CANO and CAPO Joint Symposium / Symposium annuel conjoint de l'ACIO et de l'ACOP   Facebook Live</b> Advancing Psychosocial Oncology Advocacy Across Canada: CANO/CAPO Updates and Future Directions <i>Carmen Loisele, Lorelei Newton</i> <span style="float: right;">Carson Hall Salon A</span>						
5:15pm – 6:15pm <b>Committee + SIG Meetings / Réunions du comité + du SIG</b>							
Education Committee Meeting <i>Sidney</i>		Research Committee Meeting <i>Colwood 1+2</i>		Navigation SIG Meeting <i>Langford</i>		Oncology & Aging SIG Meeting <i>View Royal</i>	
6:30pm – 8:00pm <b>Concurrent Dinner Symposia</b>							
<b>Gilead Concurrent Dinner Symposium / Souper éducatif simultané Gilead</b> <i>Saanich 1+2</i> The ABCs of ADCs in Breast Cancer <i>Dr. Sandeep Sehdev</i>			<b>GSK C19 Concurrent Dinner Symposium / Souper éducatif simultané GSK C19</b> <i>Oak Bay 1+2</i> Role of monoclonals and antivirals on early COVID treatment management <i>Dr Wayne Ghesquiere</i>		<b>BD Concurrent Dinner Symposium / Souper éducatif simultané BD</b> <i>Esquimalt</i> Safe Handling of Hazardous drugs Empowering Nurses® <i>Dr. Mikaela Olsen</i>		

**DAY THREE: SATURDAY, OCTOBER 29, 2022**  
**JOUR TROIS : SAMEDI 29 OCTOBRE 2022**

6:30am – 7:00am	<b>Morning Rejuvenation Yoga Session / Séance de yoga de rajeunissement du matin</b>						Pre-Function 2B
	Begin your day opening and preparing your body to receive knowledge. Join us for an instructor-led yoga session Commencez votre journée en ouvrant et en préparant votre corps à recevoir la connaissance. Rejoignez-nous pour une séance de yoga dirigée par un instructeur.						
7:00am – 5:30pm	Registration / Inscription						Registration Area
7:00am – 5:30pm	Speaker Services / Bureau des services aux conférenciers						Victoria
7:00am – 5:00pm	<b>Calm &amp; Quiet Lounge / Salon Calme &amp; Tranquille</b>						Metchosin
	A space to recentre, regroup and reflect / Un espace pour se recentrer, se regrouper et réfléchir						
7:00am – 8:15am	<b>Janssen Breakfast Symposium / Déjeuner éducatif Janssen</b>						Carson Hall Salon A
	Caring for Transplant-Ineligible Patients with Newly-Diagnosed Multiple Myeloma <i>Mona Walia, Michelle Forman, Rhonda Hewitt</i>						
8:30am – 9:30am	<b>CANO Annual General Meeting / Assemblée Générale Annuelle de l'ACIO   Facebook Live</b>						Carson Hall Salon A
9:45am – 10:30am	<b>CANO Awards of Excellence Ceremony / Cérémonie des prix d'excellence de l'ACIO   Facebook Live</b>						Carson Hall Salon A
10:00am – 3:30pm	Exhibit Hall Open (Final Day) / Ouverture de la salle d'exposition (Dernier jour)						Carson Hall Salon B+C
10:30am – 11:00am	Health Break & Poster Presentations Group C / Pause santé et présentations d'affiches Groupe C						Carson Hall Salon B+C
<b>Concurrent Session: 11:00am – 12:20pm A: 11:00am – 11:20am</b>	<b>Concurrent Session / Atelier simultané III-1</b> <i>Lecture Theatre</i> <b>System Impacts of COVID-19</b> 🔥 <b>A</b> - Reflection: Making the Connection Between Advanced Testicular Cancer and the COVID-19 Pandemic <i>Rebecca Stewart, Cindy Railton</i>	<b>Concurrent Session / Atelier simultané III-2</b> <i>Esquimalt</i> <b>Survivorship</b> 🔥 <b>A</b> - Preparing for Life After Primary Gynecological Cancer Treatment: An Educational Resource for Survivors and Caregivers <i>Jacqueline Galica</i>	<b>Workshop / Atelier III-3</b> <i>Oak Bay 1+2</i> 👤 Finding Hope in Difficult Times: Advancing Nursing Leadership in Climate Action <i>Aubree McAtee, Jessica Dakin</i>	<b>Concurrent Session / Atelier simultané III-4</b> <i>Saanich 1+2</i> <b>Competency Development</b> 🔥 <b>A</b> - An Integrative Review on the Oncology Nurse Navigator Role in the Canadian Context <i>Jessica Katerenchuk</i>	<b>Concurrent Session / Atelier simultané III-5</b> <i>Sidney</i> <b>Novel Approaches to Assessment</b> 🔥 <b>A</b> - Nurse-Led Telehealth Interventions for Symptom Management in Patients With Cancer: A Systematic Review <i>Dawn Stacey, Chanel Kwok, Charlena Degen, Narges Moradi</i>	<b>Concurrent Session / Atelier simultané III-6</b> <i>Colwood 1+2</i> <b>Equity in Cancer Care</b> 🔥 <b>A</b> - Dropping off the Treatment Wagon: Barriers to Cancer Treatment and Care for People Experiencing Health and Social Inequities <i>Amber Bourgeois</i>	
<b>B: 11:20am – 11:40am</b>	👤 <b>B</b> - Early New Patient Assessment at BC Cancer - Victoria: A Patient and Staff Experience Survey <i>Cloe Bailly Vignola Edwards</i>	🔥 <b>B</b> - Behind Cancer Survivorship: Three Extensive Experiential Learning Pathways <i>Karine Bilodeau, Cynthia Henriksen, Marie-France Vachon, Virginia Lee</i>		👤 <b>B</b> - Driving a Hybrid: Navigating the Road to Success in Creation of a New Brachytherapy Perioperative Course for Registered Nurses <i>Joy Bunsko, Kornelia Filipowski, Renelda Girouard</i>	👤 <b>B</b> - Telephone Completion of Patient Self-Reporting History by Registered Nurses: A Survey to Evaluate Its Effectiveness and Strategies for Improvement <i>Kelly Daigle, Mark Clemons, Nasser Alqahtani, Lisa Vandermeer, Lucia Ghadimi</i>	🔥 <b>B</b> - Health and Healthcare Equity in the Canadian Cancer Care Sector: A Rapid Scoping Review <i>Tara Horrill, Leah Lambert</i>	

**DAY THREE: SATURDAY, OCTOBER 29, 2022**  
**JOUR TROIS : SAMEDI 29 OCTOBRE 2022**

<b>C:</b> 11:40am – 12:00pm	<b>C</b> - Can You Hear Me? The Shift to Virtual Patient Education Classes During a Global Pandemic <i>Sarah Vanderhelm</i>	<b>C</b> - Exploring Post-Treatment Concerns for Survivors of Five Common Cancers: Alberta Results from the Pan-Canadian Transitions Study <i>Claire Link, Andrea Delure, Linda Watson</i>	<b>C</b> - Supporting the Novice Nurse in an Outpatient Oncology Setting: One Centre's Approach to Navigating the New Oncology Nurses' Journey From Novice to Expert <i>Jessica Dolinski, Lisa Coles</i>	<b>C</b> - The Art of Variation: Distress Screening Implementation in Rossy Cancer Network Hospitals <i>Christine Bouchard, Nathalie-El Haddad, Joséphine Lemy Dantica</i>	<b>Medical Assistance in Dying</b> <b>C</b> - Choosing MAID: Learning From Bereaved Family Members of Cancer Patients Who Chose MAID <i>Tracy Powell, Kelli Stajduhar</i>
<b>D:</b> 12:00pm – 12:20pm	<b>D</b> - Provincial Oncology Nursing Telepractice Standards Development and Evaluation during the Pandemic Response <i>Lorraine Martelli, Colleen Fox, Priyanka Jain</i>		<b>D</b> - Starting From Scratch, Growing Our Own <i>Meghan Garbutt, Cynthia Heron</i>	<b>D</b> - Examining a Nurse Practitioner-Led Intervention to Provide Supportive Care For Gynecological Cancer Survivors Entering Surveillance <i>Jacqueline Galica</i>	<b>D</b> - Patient-Targeted Resources to Support Decisions About Medical Assistance in Dying in Canada: An Environmental Scan <i>Alda Kiss</i>

**12:30pm – 2:00pm** **Jazz Pharmaceuticals Lunch Symposium / Dîner éducatif Jazz Pharmaceuticals**  
 Managing Complications of Frontline Intensive Chemotherapy for AML: A Case-Based Approach  
*Cheryl Page* Carson Hall Salon A

**12:30pm – 2:00pm** **Undergraduate and Student Day Event / Événement de la journée des étudiants et des étudiants de premier cycle** View Royal

**2:00pm – 3:00pm** **Helene Hudson Lectureship Sponsored by Amgen / Conférence Helene Hudson parrainée par Amgen | Facebook Live**  
 Moving Away From “Watch and Wait” to More Proactive Language - An NPs Approach to Reducing Distress in CLL Practice  
*Nanette Cox-Kennett* Carson Hall Salon A

**3:00pm – 3:30pm** **Health Break & Poster Presentations Group D / Pause santé et présentations d'affiches Groupe D** Carson Hall Salon B+C

<b>Concurrent Session:</b> <b>3:30pm – 4:50pm</b> <b>A:</b> 3:30pm – 4:10pm	<b>Concurrent Session / Atelier simultané</b> <b>IV-1</b> <i>Lecture Theatre</i> <b>Goals of Care</b> <b>A</b> - Goals of Care Discussion: The 7th Vital Sign for Oncology <i>Milagros Duque</i>	<b>Concurrent Session / Atelier simultané</b> <b>IV-2</b> <i>Esquimalt</i> <b>Specialized Nursing Roles</b> <b>A</b> - The Evolution of Effective Collaborative Management of PARPi Therapy in Ovarian Cancer <i>Pam Sweeney, Jolene Guenter, Katricia Kent, Michelle Mills</i>	<b>Workshop / Atelier</b> <b>IV-3</b> <i>Oak Bay 1+2</i> <b>Education</b> <b>A</b> - Together Again – Empowering New Oncology Nurses Through Education and Mentorship <i>Heather Bussey, Sarah Champ, Cynthia Heron, Laurie Ann Holmes, Kara Jamieson, Lynn Kachuik, Cheryl Page, Suganya Vadivelu</i>	<b>Concurrent Session / Atelier simultané</b> <b>IV-4</b> <i>Saanich 1+2</i> <b>Professional Wellness</b> <b>A</b> - What Have I Done for Me Lately?: Compassion Fatigue and Resilience of Oncology Team Members and the Creation of a Self-Care Space, “The Well” <i>Suzanne Scotland</i>	<b>Concurrent Session / Atelier simultané</b> <b>IV-5</b> <i>Sidney</i> <b>Patient Empowerment</b> <b>A</b> - The Role of the Patient Representative in the Cancer Patient Journey <i>Heather Purvis</i>	<b>Concurrent Session / Atelier simultané</b> <b>IV-6</b> <i>Colwood 1+2</i> <b>Symptom Burden</b> <b>A</b> - Supportive Care Needs of Young Women with Gynecological Cancer <i>Catriona Buick, Alessia Lamanna, Danielle Vicus, Lilian Gien</i>
<b>B:</b> 4:10pm – 4:30pm	<b>B</b> - Oncology Nurses' Perceptions of Advanced Care Planning: A Narrative Review <i>Heather Kilgour, Fuchsia Howard, Leah Lambert, Michael McKenzie, Sally Thorne</i>	<b>B</b> - A Primary Care Nurse (PCN) Role in the Preparation of Patients Planned for Autologous Stem Cell Transplant (ASCT) <i>Zeinab Yusuf</i>		<b>B</b> - From Wellness Baskets to Remote Anti-Cancer Drug Administration: Empowered Nurses Drive Key Covid Successes <i>Jennifer Newton, Carolyn Roberts</i>	<b>B</b> - MyChart Patient Portal: A Patient Empowerment Tool <i>Jennifer Lounsbury, Julian Owen, Yelena Potts, Faren Hill, Michele Cardusa, Wendy Bursey</i>	<b>B</b> - Understanding the Use of Telephone Triage by Cancer Patients in Alberta: Exploring the Data <i>Claire Link, Andrea Delure, Linda Watson, Siwei Qi</i>

**DAY THREE: SATURDAY, OCTOBER 29, 2022**  
**JOUR TROIS : SAMEDI 29 OCTOBRE 2022**

4:30pm – 4:50pm	<b>C - Evaluation of an Electronic Patient-Provider Communication Tool to Facilitate Goals of Care Discussions</b> <i>Shawna Ropson, Amanda Lamarche</i>	<b>C - Developing a Nurse Practitioner Lead Ambulatory Clinic for Patients with Gynecological Malignancies</b> <i>Pam Sweeney</i>	<b>C - Help We Are in Crisis – On the Path to a Stronger, More Connected Team</b> <i>Colleen Graham</i>	<b>C - Connecting and Reflecting: The Nurse Practitioner Role in Supporting Research to Assess Unmet Needs of Men Diagnosed with Testicular Cancer</b> <i>Cindy Railton</i>	<b>C - Age Analysis of Patient-Reported Outcome Measures: Understanding the Symptom Experience and Concerns of Older Albertans With Cancer</b> <i>Fay Strohschein, Claire Link, Linda Watson, Sandra Davidson, Siwei Qi</i>
5:15pm – 6:15pm	<b>CANO and Leukemia &amp; Lymphoma Society of Canada Joint Symposium / Symposium conjoint de l'ACIO et de la Société de leucémie et lymphome du Canada   Facebook Live</b> Cancer Survivorship is Everyone's Business: From the Cancer Programs to the Community <i>Karine Bilodeau, Margaret Fitch, Linda Watson, Pascale Rousseau</i>				Carson Hall Salon A
6:30pm – 11:00pm	<b>Beautiful British Columbia: Reconnection and Rejuvenation / Retrouvailles et revitalisation en Colombie Britannique</b> Doors Open 6:30 • Dinner Served 7:30 / Ouverture des portes à 18h30, repas servi à 19h30				Palm Court & Crystal Ballroom

**DAY FOUR: SUNDAY, OCTOBER 30, 2022**  
**JOUR QUATRE : DIMANCHE 30 OCTOBRE 2022**

8:00 am – 12:00pm	Registration / Inscription					Registration Area
8:00 am – 11:30am	Speaker Services / Bureau des services aux conférenciers					Victoria
7:45am – 8:15am	Breakfast / Déjeuner					Carson Hall Salon A
8:00am – 9:00am	<b>Keynote Address II / Conférence plénière II   Facebook Live</b> <b>NEW WORK HABITS FOR A CHANGING WORLD OF WORK / NOUVELLES HABITUDES DE TRAVAIL POUR UN MONDE PROFESSIONNEL EN MUTATION</b> <i>Brenda Robinson</i>					Carson Hall Salon A
<b>Concurrent Session:</b> 9:15am – 10:35am A: 9:15am – 9:55am	<b>Concurrent Session / Atelier simultané</b> <b>V-1</b> <i>Lecture Theatre</i> <b>Global Perspectives in Palliative Care</b> <b>A - The Experiences of Family Caregivers Caring for Their Relatives Diagnosed With Advanced Cancer in Ghana</b> <i>Bisi Adewale, Anna Santos-Salas, Wendy Duggleby</i>	<b>Concurrent Session / Atelier simultané</b> <b>V-2</b> <i>Esquimalt</i> <b>Innovation dans le système de soins</b> <b>French</b> <b>A - Les soins virtuels en oncologie : le point de vue du patient</b> <i>Amela Kovac, Josee Beaudet, Sabrina Lapointe, Sarah Grenier-Darveau, Yoseline Leunens</i>	<b>Workshop / Atelier</b> <b>V-3</b> <i>Oak Bay 1+2</i> <b>Research</b> <b>A - Questions You Had About Doing Cancer Care Nursing Research but Were Too Afraid to Ask</b> <i>Manon Lemonde, Christine Maheu, Jacqueline Galica, Kristen Haase, Leah Lambert, Samantha Mayo, Tracy Powell, Kylie Teggart</i>	<b>Concurrent Session / Atelier simultané</b> <b>V-4</b> <i>Saanich 1+2</i> <b>Cognition and Cancer</b> <b>A - Application of a Dynamical Neurofeedback Brain Training Intervention to Address Post-cancer Cognitive Impairment: Results of a Pilot Study</b> <i>Marian Luctkar-Flude, Jane Tyerman</i>	<b>Concurrent Session / Atelier simultané</b> <b>V-5</b> <i>Sidney</i> <b>Nursing Education</b> <b>A - Designing and Delivering a Distance Learning Oncology Nursing Graduate Certificate Program: A Step on the Path to Becoming an Oncology APN</b> <i>Linda Watson, Amy Melnick, Carol Baumgarten, Catherine Fox, Catherine Laing, Sydney Farkas</i>	<b>Concurrent Session / Atelier simultané</b> <b>V-6</b> <i>Colwood 1+2</i> <b>Patient Experience</b> <b>A - Connection, Reflection, Celebration: The Personal Impact of the Celebratory Bell in Cancer Care</b> <i>Dustin Mackay, Ava Hatcher, Grace Cole</i>

**DAY FOUR: SUNDAY, OCTOBER 30, 2022**  
**JOUR QUATRE : DIMANCHE 30 OCTOBRE 2022**

<p><b>B:</b> 9:55am – 10:15am</p>	<p><b>B</b> - A Scoping Review of Characteristics and Outcomes of Nurse-Led Palliative Care Models in Low- And Middle-Income Countries <i>Nahyeni Bassah, Anna Santos-Salas, Lisa Vaughn</i></p>	<p><b>B</b> - Implantation de l'application Belong en oncologie pour les patients et leurs familles dans leur routine de soins <i>Cory Burgher, Gabrielle Chartier, Gabrielle Rokas-Germain, Karine Lepage, Renata Benc</i></p>		<p>9:55 am – 10:35 am <b>B</b> - Connecting with People when they are Living with Cancer and Cognitive Disorders <i>Kimberly Shapkin</i></p>	<p><b>B</b> - Building Health Human Resource Capacity to Support Complex Malignant Hematology Care <i>Lorraine Martelli, Ada Payne, Colleen Fox, Jiahui Wong</i></p>	<p><b>B</b> - A Long Road Home: Challenges for Inuit Patients Wanting to Return to the North for End-Of-Life <i>Carolyn Roberts, Gwen Barton</i></p>
<p><b>C:</b> 10:15am – 10:35am</p>		<p><b>C</b> - Création d'une programme d'orientation en cancérologie (POC) panquébécois <i>Rosalie Hudon</i></p>			<p><b>C</b> - Educating Primary Care Providers About Sexual Health Disturbance in Breast Cancer Survivorship Care using Virtual Simulation: A Feasibility Study <i>Amina Silva</i></p>	<p><b>C</b> - Historical Perspectives: Gynecological Oncology Nursing and High-Dose Brachytherapy Over the Years <i>Catriona Buick, Alessia Lamanna, Elizabeth Barnes, Eric Leung</i></p>
<p>10:45am – 11:15am</p>	<p>Health Break / Pause santé</p>					
<p>10:45am – 11:15am</p>	<p><b>Metastatic Documentary Film Premiere / Première d'un film documentaire sur les métastases</b>          "Residual Splendour" documentary with Dr. Nancy Nixon and Dr. Karen Gelmon / Documentaire "Splendeur résiduelle" avec le Dr Nancy Nixon et le Dr Karen Gelmon  <i>Carson Hall Salon A</i></p>					
<p>11:15am – 12:15pm</p>	<p><b>Clinical Award Lectureship Sponsored by Merck / Conférence et remise de prix parrainée par Merck   Facebook Live</b>          Collaborating Across Settings to Shape the Future of Oncology Nursing After-Hours Toxicity Management Support  <i>Lorraine Martelli, Sherry Hnatyshyn-Webster</i>  <i>Carson Hall Salon A</i></p>					
<p>12:15pm – 12:45pm</p>	<p><b>Closing Ceremonies and Abstract Awards Presentation / Cérémonie de clôture et remise de prix pour abrégés   Facebook Live</b>  <i>Carson Hall Salon A</i></p>					

# Poster Presentations / Séance d'affichage

## VOTE FOR THE POSTER AWARDS / VOTEZ POUR LE PRIX POSTER

Delegates are asked to vote for their top 3 posters in each category EDUCATION, CLINICAL, and RESEARCH. The top poster in each category wins \$150 and 2nd place wins \$75. Please vote by: Saturday, October 30 at 5:00 PM PST.

Les délégués sont invités à voter pour leurs trois affiches préférées dans chaque catégorie : ÉDUCATION, PRATIQUE CLINIQUE et RECHERCHE.

La meilleure affiche de chaque catégorie recevra 150 \$ et la deuxième place recevra 75 \$. Veuillez voter avant samedi, le 30 octobre à 17h00 PST.

### POSTER STATION #1 / POSTE D'AFFICHAGE N° 1

### POSTER STATION #2 / POSTE D'AFFICHAGE N° 2

#### Group A – Clinical • Friday, October 28, 2022: 10:15 am – 10:45 am

10:15 am – 10:25 am	Nursing Led Benchmarking Project: Exploring Nurses' role across Diagnostic Breast Centers <i>Gabrielle Chartier, Lindsay Schwartz, Rajshree Patel</i>	Venipuncture in the Affected Limb of Patients With Breast Cancer: Translating Knowledge to Practice Using the Implementation Roadmap <i>Michelle Harbott, Heather Kilgour, Jagbir Kaur, Korenelia Filipowski, Scott Beck</i>
10:25 am – 10:35 am	Facilitators and Barriers in Oncology Clinical Practice Influencing Nurses' Completion of GRASP Workload Measurement System to Ensure Patient-Centered <i>Anita Long, Eleonora Cretu, Kalliopi Stillos</i>	COVID-19 Isolation Precautions in Immunocompromised Oncology Patients <i>Ha Pham, Eric Bow, Mackenzie Jansen</i>
10:35 am – 10:45 am	Effectiveness of a Standard Screening Program for Intravenous Immunoglobulin at Community Hospital <i>Amina Malik, Ashmina Damani</i>	

#### Group B – Clinical, Leadership & Foundational Knowledge • Friday, October 28, 2022: 3:30 pm – 4:00 pm

3:30 pm – 3:40 pm	Enteral Versus Parenteral Nutrition - What is the Best for Stem Cell Transplants? <i>Phillip Nguyen, Kristen Brazel, Leslie Lepage</i>	The Ontario Peritoneal Surface Malignancy Program <i>Sophia Aksenchuk</i>
3:40 pm – 3:50 pm	Optimizing Oncology Nursing Scope of Practice with the Added Competency of Tuberculosis Testing in an Outpatient Setting <i>Samantha Soto, Jennifer Sunga</i>	Re-Designing the ESAS-r for Ambulatory Oncology Settings: Exploring Fit, Reliability and Validity <i>Claire Link, April Hildebrande, Andrea Delure, Lindsy Chmielewski, Louise Smith, Linda Watson</i>
3:50 pm – 4:00 pm	A Quality Project on Improving Patient Safety: Prostate Biopsy <i>Amina Malik, Laura Alexander</i>	

#### Group C – Research • Saturday, October 29, 2022: 10:30 am – 11:00 am

10:30 am – 10:40 am	Informal Caregivers in Palliative Care Planning: Perception, Documentation, and Integration <i>Jacob Loong, Charlotte Lee, Jason Wong, Lauren Lovold, Melanie Honsinger</i>	Addressing Hematologic Cancer Symptom Burden Through Evidence-Informed Oncology Nursing Practice: Protocol for an Experience-Based Co-design Study <i>Kylie Teggart, Denise Bryant-Lukosius, Jennifer Lonsbury, Margaret Forbes, Nancy Carter, Rebecca Gannan</i>
10:40 am – 10:50 am	Cancer Screening for Refugees in OECD Countries: A Realist Review <i>Angille Heintzman, Michelle Lafreniere</i>	Support Interventions Offered to Family Members of a Child Treated with HSCT <i>Pauline Shapton</i>
10:50 am – 11:00 am	The Process of Developing a Survey that Examines the Experience of Oncology Nurses in Providing Virtual Care <i>Jacob Loong, Caitlin Turney, Catriona Buick, Charlotte Lee, Jason Wong, Sue Bookey-Bassett</i>	

#### Group D – Education • Saturday, October 29, 2022: 3:00 pm – 3:30 pm

3:00 pm – 3:10 pm	Patient Education Development for the New Normal <i>Carrie Mazoff, Renata Benc</i>	RN Reviewers for Systemic Therapy Protocols <i>Gurjeevan Dosanjh</i>
3:10 pm – 3:20 pm	The Use of Simulation-Based Education in Cancer Care: A Scoping Review <i>Amina Silva</i>	JCURA Student Journey to Cancer Care Nursing <i>Claire Fullerton</i>
3:20 pm – 3:30 pm	Virtual Systemic Therapy Patient Education Project <i>Sarah Felber</i>	Implementing a Dementia-Friendly Care Approach for Cancer Patients Living with Dementia <i>Shelley Canning</i>

# Sponsor and Exhibitor Profiles / Profils de commanditaires et exposants

## ☆ ABBVIE

*Sponsorship: Silver/Argent*

AbbVie is a company that takes on the toughest health challenges. But we do more than treat diseases—we aim to make a remarkable impact on people's lives. We are AbbVie, a highly focused research-driven biopharmaceutical company.

## ☆ AMGEN

*Sponsorship: Bronze/Bronze, Award*

Amgen discovers, develops, manufactures, and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease, cardiovascular disease and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. For more information, visit [www.amgen.ca](http://www.amgen.ca)

## ☆ APOBIOLOGIX

*Sponsorship: Silver/Argent*

Apobiologix®, a division of Apotex Inc., focuses on the commercialization of biosimilars. The Apobiologix® biosimilar program is a natural extension of Apotex' long history of providing access to high-quality, affordable medicines in Canada and across the globe. We aspire to transform access to affordable therapies in oncology and beyond through innovation, development, and partnerships. At Apobiologix®, we believe Innovation is not the only Innovation; we believe healthcare providers and patients deserve access to affordable therapies without compromising efficacy, quality, and safety.

## ☆ ASTELLAS

*Sponsorship: Gold/Or*

Astellas Pharma Canada, Inc., headquartered in Markham, ON, is a Canadian affiliate of Tokyo-based Astellas Pharma Inc. Astellas is dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. In Canada, Astellas has an intense commercial focus on four therapeutic areas – Urology, Immunology, Infectious Disease and Oncology. For more information about Astellas Pharma Canada, Inc., please visit the corporate website: [www.astellas.ca](http://www.astellas.ca)

## ☆ ASTRAZENECA CANADA

*Sponsorship: Platinum/Platine, Symposium, Focus Group*

AstraZeneca is a global, innovation-driven biopharmaceutical business with a focus on the discovery, development and commercialization of primary and specialty care medicines that transform lives. Our primary focus is on four important areas of healthcare: Cardiovascular, Renal and Metabolic disease; Oncology; Respiratory & Immunology; and Rare Diseases. AstraZeneca operates in more than 100 countries and its innovative medicines are used by millions of patients worldwide. In Canada, we employ roughly 1,090 employees across the country and our headquarters are located in Mississauga, Ontario. For more information, please visit the company's website at [www.astrazeneca.ca](http://www.astrazeneca.ca).

## ☆ B. BRAUN

*Sponsorship: Exhibitor/Exposant*

Propelled by our philosophy of Sharing Expertise®, B. Braun of Canada is a leader in infusion therapy, safe and efficient pharmacy, and clinical support services. At B. Braun, we provide the tools and services healthcare providers need to deliver an optimal patient experience—improving outcomes across your health systems today, while continuously striving for a better tomorrow. All while focusing on clinical practice, safety, satisfaction and sustainability in an evidence-based world. You'll find our products, technology and services in top hospitals across North America. Helping to

empower providers so they can deliver the best possible experience. It's why we exist.

## ☆ BC CANCER

---

**Sponsorship:** Exhibitor/Exposant

BC Cancer provides a province-wide, comprehensive cancer control program, covering the full spectrum of cancer care from prevention, screening, diagnosis and treatment, to research and education, to supportive and palliative care. Recognized internationally for cutting-edge cancer care, treatment, and research, BC Cancer's person-centred cancer care is delivered through six regional cancer centres – Vancouver, Victoria, Surrey, Abbotsford, Prince George, Kelowna – providing assessment and diagnostic services, chemotherapy, radiation therapy, and supportive care. BC Cancer nurses are essential members of the health care teams, working collaboratively to support the highest standards of care and the latest, evidence-based treatment options for patients and their families.

## ☆ BD

---

**Sponsorship:** Exhibitor/Exposant

BD is one of the largest global medical technology companies in the world and is advancing the world of health™ by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of healthcare by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for healthcare providers. BD and its 75,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to healthcare.

## ☆ BEIGENE

---

**Sponsorship:** Silver/Argent

At BeiGene, we are guided by a fundamental belief that patients deserve access to innovative medicines at affordable prices regardless of where in the world they live. To bring life-saving therapies to more patients more quickly, BeiGene leverages global clinical trials to develop high-quality medicines in shorter timeframes than the average clinical trial.

We transcend borders, time zones, and especially the status quo to develop therapies that are more accessible to people around the world. As part of our global clinical development program, we're enrolling patients in 40+ countries and geographies to participate in our clinical trials.

Cancer has no borders. Neither do we.

## ☆ BIOSCRIPT SOLUTIONS

---

**Sponsorship:** Exhibitor/Exposant

For more than 20 years, BioScript Solutions has helped patients with chronic illnesses and rare diseases access the complex drug therapies they need. We provide full-service specialty care solutions, working closely with you as a partner to streamline processes, remove barriers, and deliver efficiencies that support the best possible health outcomes for your patients. Our knowledgeable, skilled team act as an integral part of your patients' extended health care team – becoming your true partner in care. From our home base in Atlantic Canada, we've grown into a national network of more than 100 clinics, 13 pharmacies, and comprehensive patient support programs.

## ☆ BOIRON

---

**Sponsorship:** Exhibitor/Exposant

With 85 years of experience in manufacturing homeopathic medicines, Boiron takes great pride in providing Canadians with medicines that are "as pure and perfect as possible".

Every day, we place our passion and expertise in homeopathic medicines at the service of health care practitioners and patients.

- 85 years of expertise
- 3600 people on the Boiron team
- 30 years in Canada

As a result, today, there are 3,600 people on the Boiron team with 20 foreign subsidiaries, four production facilities in France, and distribution in 50 countries. With a presence in Canada for 30 years, Boiron Canada is proud to provide Canadians with simple and effective solutions for self-medication. You can rely on Boiron medicines for your whole family, from newborns to the elderly.

## ☆ BRISTOL MYERS SQUIBB

*Sponsorship: Silver/Argent*

At Bristol Myers Squibb, we work every day to help patients. Patients are at the center of everything we do. They inspire us. They are the reason we come to work each day. We aspire to be at the center of a vibrant healthcare ecosystem, where academic research centers, biotech and biopharma companies all contribute to continued scientific advancement.

## ☆ CANADIAN CANCER SOCIETY

*Sponsorship: Exhibitor/Exposant*

At the Canadian Cancer Society, we are committed to uniting and inspiring Canadians to take control of cancer. That's why we are always funding high performance research that improves cancer outcomes and addresses the greatest opportunities for progress. It's why we lead change in the most pressing areas of cancer policy including prevention, access, affordability, and support. And it's why we provide the highest quality cancer information for all Canadians, promote cancer prevention and provide targeted support to help people with cancer, their families and caregivers cope.

We set ourselves apart from other cancer charities by taking a comprehensive approach against cancer.

## ☆ CANADIAN NEUROENDOCRINE TUMOUR SOCIETY (CNETS)

*Sponsorship: Exhibitor/Exposant*

The Canadian Neuroendocrine Tumour Society (CNETS), provides awareness, education, advocacy and support to NET patients, families and caregivers. Working in collaboration with medical and scientific experts, stakeholders and partner associations, CNETS is the only Canadian charity supporting the NET community by:

- Helping NET patients obtain personalized diagnostic and therapeutic options

- Advocating on behalf of individual patients and for policies to support NET patients
- Providing workshops and seminars on NET-related subjects
- Establishing local support groups to provide support services for those affected by NETs

CNETS is committed to improving the quality of life and survival for NET patients across Canada.

## ☆ CANADIAN VASCULAR ACCESS ASSOCIATION

*Sponsorship: Exhibitor/Exposant*

CVAA is a Canadian, non-profit multi-disciplinary organization of healthcare professionals who are dedicated to enhancing the practice of vascular access and infusion therapy. CVAA empowers and engages its members to advocate for safe, quality care across the healthcare continuum by providing leadership and promoting education, partnerships, knowledge and research in vascular access and infusion therapy with a vision for optimal patient outcomes. We have local chapters, a peer-reviewed journal, Guidelines, and an exciting global partnership conference coming up in April 2023 in Toronto! Come say hello!

## ☆ CANADIAN NURSES ASSOCIATION

*Sponsorship: Exhibitor/Exposant*

CNA is the national and global professional voice of Canadian nursing. Our mission is to advance the nursing profession to improve health outcomes in Canada's publicly funded, not-for-profit health system. CNA is the only national association that speaks for all types of nurses across all 13 provinces and territories. We represent nurses that are unionized and non-unionized, retired nurses, nursing students, and all categories of nurses (registered nurses, nurse practitioners, licensed and registered practical nurses, and registered psychiatric nurses).

## ☆ DE SOUZA INSTITUTE

*Sponsorship: Exhibitor/Exposant*

de Souza Institute is a continuing education program at University Health Network, one of the leading hospitals in scholarship, innovation and clinical care. Through our online courses, we offer easy access to continuing education in oncology and palliative care that reflects best practices. Our learning pathway supports nurses new to oncology to build foundational knowledge and

obtain more advanced skills. The 35+ course selection covers a broad range of topics from cancer prevention, treatment, symptom management to survivorship and palliation. The On-Demand courses allow busy clinicians across Canada to expand their knowledge on their own schedule and pace.

### ☆ ELECRAE

*Sponsorship: Exhibitor/Exposant*

Elecrae Compression is a Vancouver based medical grade compression sock company that heard the voices of the front line staff to deliver a high quality compression stocking with fun designs. Elecrae compression socks are perfect for travel, work, running and everyday wear. Our mission is to give those tired legs the love they need! Elecrae compression socks provide visual joy with a luxurious feel and added relief throughout your day.

### ☆ ELI LILLY

*Sponsorship: Silver/Argent*

Eli Lilly Canada Inc. was established in 1938, the result of a research collaboration with scientists at the University of Toronto, which eventually produced the world's first commercially-available insulin. Our work focuses on oncology, diabetes, autoimmunity, neurodegeneration, and pain. To learn more about Lilly Canada, please visit us at [www.lilly.ca](http://www.lilly.ca).

### ☆ EMD SERONO AND PFIZER CANADA

*Sponsorship: Gold/Or, Symposium*

**EMD Serono** is the Canadian biopharmaceutical business of Merck KGaA, Darmstadt, Germany, with innovative products and devices, and industry-leading patient support and access programs. EMD Serono has deep expertise in neurology, fertility and endocrinology, and a pipeline in neurology, oncology, immunology and immuno-oncology. EMD Serono is headquartered in Mississauga, Ontario.

Pfizer Canada ULC is the Canadian operation of Pfizer Inc., one of the world's leading biopharmaceutical companies. Our diversified health care portfolio includes some of the world's best known and most prescribed medicines. To learn more about Pfizer Canada, visit [pfizer.ca](http://pfizer.ca) or you can follow us on LinkedIn, Facebook, Twitter or YouTube.

### ☆ EUSA PHARMA

*Sponsorship: Bronze/Bronze*

At EUSA we are committed to transforming the lives of people affected by cancer or rare disease, globally. We continuously strive to uncover opportunities which address gaps across adult and paediatric care - through development opportunities, acquiring, and in-licensing therapies. Helping the people with few or no options available is at the heart of everything we do at EUSA. Every day, we are proud to make a difference - building a company around our people, our values, and our mission. We see a need. We work together. We don't give up.

### ☆ FORUS THERAPEUTICS

*Sponsorship: Exhibitor/Exposant*

FORUS Therapeutics Inc. is a newly founded, fast-growing Canadian biopharmaceutical company dedicated to making a profound difference for Canadian patients, health care professionals and caregivers by advancing differentiated novel medicines for hematologic malignancies and other forms of cancer.

### ☆ GILEAD AND KITE ONCOLOGY

*Sponsorship: Gold/Or, Symposium, Focus Group*

Gilead and Kite Oncology are creating the future of oncology. From ADCs and small molecules to cell therapy, our R&D programs and partnerships are focused on helping to bring more life to people with cancer and changing the way cancer is treated.

### ☆ GSK

*Sponsorship: Gold/Or, Symposium*

As a science-led global healthcare company, GSK is committed to improving quality of life and outcomes for patients with gynecologic cancers through the development of a robust pipeline of transformative medicines.

En tant que société mondiale de soins de santé axée sur la science, GSK s'engage à améliorer la qualité de vie et les résultats pour les patientes atteintes de cancers gynécologiques grâce à la mise au point d'une solide gamme de médicaments prometteurs en développement.

## ☆ GSK C19

*Sponsorship: Sponsorship: Exhibitor/Exposant*

As a science-led global healthcare company, GSK is committed to improving quality of life and outcomes for patients with gynecologic cancers through the development of a robust pipeline of transformative medicines.

## ☆ ICU MEDICAL

*Sponsorship: Exhibitor/Exposant*

ICU Medical helps you deliver IV oncology safely with a complete line of closed system transfer devices (CSTDs) that align with industry safe-handling guidelines and award-winning infusion pumps with full IV-EHR interoperability. Our intuitive luer-based and needle free CSTDs are designed to help keep healthcare workers safe during every step of the hazardous drug process, from preparation to transportation, administration, and disposal. Connect Smarter. Care Safer.™ Visit [www.icumed.com](http://www.icumed.com) to learn more.

## ☆ INCYTE

*Sponsorship: Bronze/Bronze*

Incyte Biosciences Canada is dedicated to the discovery, development, and commercialization of therapeutic options for serious conditions.

## ☆ INNOVATIVE ONCOSOLUTIONS

*Sponsorship: Exhibitor/Exposant*

Innovative Oncosolutions Inc. (IOS) is a Canadian owned medical company focused on products that ensure safety and compliance in healthcare settings. Specifically, IOS is the distributor of Equashield™, the most advanced closed system drug transfer device (CSTD) for safe preparation and administration of hazardous drugs.

Compliance in pharmacy settings has become increasingly important. To ensure this compliance, IOS offers Compounding 360, a cloud based NAPRA compliant quality management system providing a comprehensive electronic audit and quality assurance program. In addition, IOS offers Third-Party Sterile Compounding Certification Services on-site or virtually by our annually certified Registered Pharmacy Technician.

## ☆ IPSEN BIOPHARMACEUTICALS

*Sponsorship: Gold/Or*

Inspiring hope, improving patients' lives

Acting on this mission has propelled us to become a global biopharmaceutical leader with a focus on innovation and specialty care.

Our passion drives our commitment to patients living with difficult-to-treat diseases, and we put them first. Because patients are our priority, we help them through our expertise in oncology, neuroscience, and rare disease.

We bring medicines to patients with the strength of nearly 6,000 employees across the globe, including innovators in our key therapeutic areas.

## ☆ JANSSEN

*Sponsorship: Gold/Or, Symposium*

Missing Profile

## ☆ JAZZ PHARMACEUTICALS

*Sponsorship: Gold/Or, Symposium, Focus Group*

At Jazz Pharmaceuticals plc (NASDAQ: JAZZ), our purpose is to innovate to transform the lives of patients and their families. We are focused on developing life-changing medicines for people with serious diseases — often with limited or no options— so they can live their lives more fully. By transforming biopharmaceutical discoveries into novel medicines, we are working to give people around the world the opportunity to redefine what's possible — to make the "small wins" big again. We are a fully integrated, global biopharmaceutical company with a diverse portfolio of marketed medicines and novel product candidates for adults and children, and expertise in two key therapeutic areas: neuroscience and oncology. We are an industry leader in treating sleep disorders and epilepsy, and in oncology we are investigating and delivering medicines for hard-to-treat hematologic malignancies and solid tumors. We use our deep knowledge of and commitment to these fields to innovate and identify new solutions where none previously existed.

## ☆ LA ROCHE POSAY

*Sponsorship: Gold/Or*

La Roche Posay is the number 1 dermo-cosmetic brand worldwide and is the #1 recommended skincare brand by dermatologists in Canada. Our mission for our oncology engagement is to help cancer patients undergoing chemotherapy and radiation treatments, with a focus on improving patient quality of life by reducing skin side effects with the help of our safe, tolerable, and effective skin care products. Having conducted various studies with over 1,100 patients undergoing cancer treatments, La Roche-Posay has demonstrated efficacy in achieving this for oncology patients, by reducing skin side effects as well as improve quality of life.

## ☆ LEO PHARMA

*Sponsorship: Bronze/Bronze*

LEO Pharma Canada is a division of LEO Pharma A/S, a global research-based pharmaceutical company, specializing in skin health and thrombosis (blood-clots). For more than a century, and for over 30 years in Canada, our focus has been on improving the quality of patients' lives. We are expanding into new markets, to reach more patients with innovative treatments to address unmet medical needs. LEO Pharma has been developing products for people with blood clot disorders for more than 50 years. We listen to how people experience living with these life-critical conditions – to develop treatments to make their lives as comfortable as possible.

## ☆ LEUKEMIA AND LYMPHOMA SOCIETY

*Sponsorship: Exhibitor/Exposant*

The mission of the Leukemia and Lymphoma Society is to cure blood cancers and improve the quality of life of people affected and their families by funding life-enhancing research and providing educational resources, services and support. We are the largest registered charitable health agency dedicated to supporting the blood cancer community in Canada. Our focus has grown and now includes:

- Funding research from bench to bedside
- Help people navigate their blood cancer experience
- Providing targeted blood cancer information

- Offering tools for psychological and emotional support
- Empowering Canadians to take charge of their blood cancer experience through practical support and advocacy

La mission de la Société de leucémie et lymphome du Canada est d'améliorer la qualité de vie des personnes touchées par un cancer du sang et de leurs familles en finançant la recherche et en offrant des services et du soutien. Nous:

- Finançons des recherches de pointes, du banc d'essai aux soins
- Aidons les personnes touchées et les familles à naviguer l'expérience du cancer du sang;
- Fournissons de l'information ciblée sur le cancer du sang;
- Offrons des outils de soutien psychologique et émotionnel;
- Offrons du soutien pratique et aidons les canadiens touchés à défendre leurs droits

## ☆ MELANOMA CANADA

*Sponsorship: Exhibitor/Exposant*

Melanoma Canada is a national organization dedicated to advocating for and supporting Canadians living with melanoma and skin cancer with helpful resources, education, psychosocial support services, and more.

Support melanoma and skin cancer patients, caregivers, and medical professionals through current and coordinated information and resources

To educate Canadians on melanoma and skin cancer including prevention, early detection, and available treatment options.

To be the united voice of the melanoma and skin cancer community, advocating for early detection, a timely diagnosis, and effective treatment options.

Contact Melanoma Canada today 1.866.560.8035 or visit [melanomacanada.ca](http://melanomacanada.ca)

## ☆ MERCK

---

*Sponsorship: Bronze/Bronze, Award*

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals.

## ☆ MERCK ASTRAZENECA CANADA

---

*Sponsorship: Platinum/Platine, Focus Group*

AstraZeneca is a science-led biopharmaceutical company pushing the boundaries of science to deliver life-changing medicines.

The company employs roughly 900 people in Canada who work to research, develop and market innovative medicines. AstraZeneca Canada was recently designated a global Clinical Hub for oncology and immuno-oncology clinical studies. We are currently leading global oncology clinical studies in lung, head and neck cancer.

The future of treatment for many of today's diseases lies in uncovering mechanisms that are newly emerging or are still to be discovered. We believe the best way to help patients is to focus on breakthrough science to discover these mechanisms and develop novel, targeted therapies that interact with them. Our focus is on the following core therapy areas: Cardiovascular, Renal and Metabolic diseases (CVRM); Oncology; and Respiratory & Immunology.

In 2019, AstraZeneca invested more than \$145 million in Canadian health sciences research in our core therapy areas.

AstraZeneca Canada was named one of Canada's 10 Most Admired Cultures in 2020 by Waterstone Human Capital – a national award that recognizes best-in-class Canadian organizations with a commitment to strong and vibrant corporate cultures anchored to their people and values. The company was also recognized as being one of the top employers in the Greater Toronto Area –

the seventh consecutive year AstraZeneca has received a Greater Toronto Top Employer Award.

At Merck Canada, we are inspired by a shared vision and mission to save and improve lives. To make a difference in the lives of people through our innovative medicines, vaccines, and animal health products. We are committed to being the premier, research-intensive biopharmaceutical company and are dedicated to providing leading innovations and solutions for today and the future.

## ☆ NESTLE HEALTH SCIENCES

---

*Sponsorship: Exhibitor/Exposant*

Nestlé Health Science empowers healthier lives through nutrition.

Through Science of nutrition, we nourish those who need extra care, fill nutrition gaps and provide innovative products for a healthier future, enabling customers and patients to live their healthiest lives. Backed by science and focused on sustainability, we create products to help people live their healthiest lives.

## ☆ NIPRO CANADA

---

*Sponsorship: Bronze/Bronze*

Nipro Canada formerly CardioMed Supplies would like to welcome the return of in-person meetings and we hope that your CANO 2022 meeting supports both education and collaboration. We're very pleased to introduce several new patient quality initiatives that have been proven with evidence-based articles. Please visit our booth and one of our representatives will assist you. Enjoy CANO 2022!

## ☆ PFIZER CANADA

---

*Sponsorship: Platinum/Platine, Symposium, Focus Group, Award*

Pfizer Canada ULC is the Canadian operation of Pfizer Inc., one of the world's leading biopharmaceutical companies. Our diversified health care portfolio includes some of the world's best known and most prescribed medicines and vaccines. At Pfizer, our colleagues work to deliver Breakthroughs that change patients' lives™. In 2019, Pfizer Inc. invested US\$ 8.65 billion globally toward developing safe and effective medicines and took part in more than 95 new R-D collaborations. Global headquarters are located in New York City, where the company was founded in 1849.

Pfizer's Canadian footprint includes its headquarters in Kirkland, Quebec and a manufacturing site in Brandon, Manitoba. To learn more about Pfizer Canada, visit [pfizer.ca](http://pfizer.ca) or you can follow us on LinkedIn, Facebook, Twitter or YouTube.

Pfizer Canada SRI est la filiale canadienne de Pfizer Inc., l'une des principales entreprises biopharmaceutiques à l'échelle mondiale. Notre gamme diversifiée de produits de soins de santé comprend des médicaments et des vaccins figurant parmi les plus connus et les plus prescrits dans le monde. Tous les jours, les employés de Pfizer Canada travaillent dans le but de réaliser des percées qui changent la vie des patients. Nous mettons à profit la science et nos ressources mondiales pour améliorer la santé et le bien-être de la population canadienne, à toutes les étapes de la vie. Notre engagement se reflète dans tout ce que nous faisons, qu'il s'agisse d'initiatives de sensibilisation aux maladies ou de partenariats communautaires. Pour en savoir plus sur Pfizer Canada, visitez le site [pfizer.ca](http://pfizer.ca) ou suivez-nous sur LinkedIn, Facebook, Twitter ou YouTube.

## ☆ SANOFI

**Sponsorship: Bronze/Bronze**

At Sanofi, we chase the miracles of science to improve people's lives. Our determination to find answers for patients motivates us to develop breakthrough medicines and vaccines. Fueled by data and digital technologies, our cutting-edge science and manufacturing have the potential to transform the practice of medicine, turning the impossible into possible for millions of people around the world.

Our Specialty care team focuses on developing therapies for debilitating diseases that are often difficult to diagnose and treat, providing hope to patients and their families, in the areas of rare blood disorders, neurology, oncology, and immunology.

## ☆ SAVE YOUR SKIN

**Sponsorship: Exhibitor/Exposant**

Save Your Skin Foundation (SYSF) is a patient-led not-for-profit organization dedicated to the fight against non-melanoma skin cancers, melanoma, and ocular melanoma through education, advocacy, and awareness initiatives across Canada. SYSF provides a community of oncology patient and caregiver support

throughout the entire continuum of care, from prevention and diagnosis to survivorship.

SYSF is also the Secretariat of All.Can Canada, a national, multi-stakeholder platform for cancer care efficiency, with a preliminary aim of optimizing people's entry into cancer care through swift, accurate, and appropriately delivered diagnosis.

## ☆ SEAGEN

**Sponsorship: Bronze/Bronze**

Seagen is a global biotechnology company that discovers, develops, and commercializes medicines for cancer. The company has a pipeline of therapies at various stages of preclinical testing, clinical testing, and development. We are leveraging our expertise in antibodies to build a portfolio of proprietary antibody-drug conjugates and immune-oncology agents in clinical trials for hematologic malignancies and solid tumors. For more information, visit [www.seagen.ca](http://www.seagen.ca).

## ☆ SPECTRUM THERAPEUTICS

**Sponsorship: Exhibitor/Exposant**

Canopy is a global, best-in-class cannabis company and CPG organization with the intention to unleash the power of cannabis to improve lives. From expanding personal health and wellness to creating economic opportunity and working on social justice initiatives, Canopy is demonstrating the ability of cannabis as a positive agent for change.

Spectrum Therapeutics is an international medical cannabis brand that raises the standard of care for patients with unmet medical needs. We make it easy for patients and healthcare professionals to optimize the therapeutic benefits of medical cannabis.

## ☆ TAKEDA

**Sponsorship: Silver/Argent**

Better Health, Brighter Future

Our way to better health is by advancing science to develop leading innovations in gastroenterology, oncology, neuroscience, and rare diseases to meet the needs of Canadians. Takeda Canada is one of the fastest-growing pharmaceutical companies in Canada. To find out more about Takeda Canada and our commitment to Canadians, visit [www.takeda.com/en-ca](http://www.takeda.com/en-ca).

## ☆ TEVA

Sponsorship: Bronze/Bronze

At Teva, we understand that the Canadian healthcare market is changing with the increased availability of biosimilars. For that reason, we are focusing our research and development efforts on providing innovative products that healthcare providers and consumers can trust. With over 1,200 products currently available, we are committed to expanding our portfolio and continuing to help Canadians.

## ☆ VIATRIS

Sponsorship: Bronze/Bronze

We believe in healthcare as it should be – empowering people worldwide to live healthier at every stage of life. Because of our unwavering belief that better access leads to better health, we leverage our best-in-class manufacturing and scientific expertise and proven commercial capabilities to bring quality medicines to patients when and where they need them. Our oncology portfolio consists of: Ogivri (trastuzumab), FULPHILA (pegfilgrastim), ABEVMY (bevacizumab), CREON (pancrelipase), Bendamustine, Hydroxyurea and Ondansetron.



**INDICATED IN**  
**non-small cell lung cancer (NSCLC), basal cell carcinoma (BCC)**  
**and cutaneous squamous cell carcinoma (CSCC)<sup>1</sup>**



LIBTAYO (cemiplimab for injection) is indicated for:

- the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation.

LIBTAYO has been issued marketing authorization with conditions, pending the results of trials to verify its clinical benefit. Patients should be advised of the nature of the authorization. For further information for LIBTAYO please refer to Health Canada's Notice of Compliance with conditions - drug products website: <https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/notice-compliance/conditions.html>.

Marketing authorization with conditions is based on tumour response rate and durability of response. An improvement in overall survival (OS) or progression-free survival (PFS) has not yet been established in this single-arm study.

LIBTAYO (cemiplimab for injection) is also indicated for:

- the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 in  $\geq 50\%$  of tumour cells (Tumour Proportion Score [TPS]  $\geq 50\%$ ), as determined by a validated test, with no EGFR, ALK or ROS1 aberrations, who have:
  - locally advanced NSCLC who are not candidates for surgical resection or definitive chemoradiation, or
  - metastatic NSCLC.
- the treatment of patients with locally advanced basal cell carcinoma (BCC) previously treated with a hedgehog pathway inhibitor.

LIBTAYO has been issued market authorization without conditions for BCC and NSCLC.

Please consult the LIBTAYO Product Monograph at <http://products.sanofi.ca/en/libtayo.pdf> for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling us at 1-800-265-7927.

LIBTAYO<sup>®</sup> and Sanofi logos are trademarks of Sanofi, used under license by sanofi-aventis Canada Inc. © 2022 sanofi-aventis Canada Inc.

All rights reserved. MAT-CA-2101390-E

Reference:

1. "LIBTAYO" Product Monograph, sanofi-aventis Canada Inc. March 23, 2022.

sanofi

**34<sup>TH</sup>** EME  
**ANNUAL CONFERENCE**  
**CONFÉRENCE ANNUELLE**

**OCTOBER 27-30, 2022**  
Victoria Convention Centre and  
Fairmont Empress Hotel

**LA ROCHE-POSAY**  
LABORATOIRE DERMATOLOGIQUE

**81%**

OF PATIENTS THAT UNDERGO ANTI-CANCER TREATMENTS ARE EXPECTED TO EXPERIENCE SKIN SIDE EFFECTS<sup>1</sup>.

1-Charles C. Sautan S., Bungeener C. et al. March 2018. Impact of cutaneous toxicity associated with targeted therapies on quality of life. Results of a longitudinal exploratory study. Bulletin du Cancer, Vol. 100 N°3

**SOOTHE, RELIEVE AND PROTECT THEIR SKIN  
WITH LA ROCHE-POSAY**

**PROUD SPONSOR OF CANO**



**PrALUNBRIG® (brigatinib)** is indicated as a monotherapy for the **first-line treatment** of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC).

Consult the Product Monograph at [www.takeda.com/en-ca/alunbrigpm](http://www.takeda.com/en-ca/alunbrigpm) for important information on contraindications, warnings, precautions, adverse reactions, interactions, dosing and conditions of clinical use. The Product Monograph is also available by calling us at 1-800-268-2772.

**Reference:** ALUNBRIG® Product Monograph. Takeda Canada Inc. March 2, 2021.



**ONCOLOGY**

Takeda Canada Inc.  
Bay Adelaide Centre  
22 Adelaide Street West, Suite 3800  
Toronto, Ontario M5H 4E3  
<https://www.takeda.com/en-ca>

ALUNBRIG® and the ALUNBRIG Logo® are registered trademarks of ARIAD Pharmaceuticals, Inc. TAKEDA™ and the TAKEDA Logo® are trademarks of Takeda Pharmaceutical Company Limited, used under license. © 2022 Takeda Pharmaceutical Company Limited. All rights reserved.

PRMCDA/CA/ALUN/0037E



# COULD YOU HELP GIVE HIM MORE TIME?

REIMBURSED IN MOST  
PROVINCES (SPECIAL  
AUTHORIZATION) – CHECK  
YOUR LOCAL FORMULARY

NOW BOARDING

IN RELAPSED OR REFRACTORY *FLT3*-MUTATED AML,

**XOSPATA<sup>®</sup> HELPED PROLONG OVERALL  
SURVIVAL (OS) VS. SALVAGE CHEMOTHERAPY**  
(HR = 0.637; 95% CI: 0.49–0.83; 1-sided *p*-value = 0.0004)<sup>†,1</sup>

Percentage of deaths: 69.2% (171/247) in the XOSPATA arm vs.  
72.6% (90/124) in the salvage chemotherapy arm.<sup>1</sup> Median OS was  
9.3 months (95% CI: 7.7–10.7) with XOSPATA vs. 5.6 months  
(95% CI: 4.7–7.3) with salvage chemotherapy.<sup>1</sup>

## Indication and clinical use:

XOSPATA (gilteritinib) is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (*FLT3*) mutation. A validated test is required to confirm the *FLT3* mutation status of AML.

XOSPATA is not indicated in pediatric patients (< 18 years of age). In clinical trials, no overall differences in efficacy or safety were observed in patients 65 years or older compared to younger patients.

## Contraindication:

XOSPATA is contraindicated in patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container.

## Most serious warnings and precautions:

**Differentiation syndrome:** Risk of differentiation syndrome. Differentiation syndrome was reported in patients treated with XOSPATA. Symptoms and clinical findings may include fever, dyspnea, pleural effusion, pericardial effusion, pulmonary infiltrate, hypotension, rapid weight gain, peripheral edema, rash, and renal dysfunction. Some cases had concomitant acute febrile neutrophilic dermatosis. Differentiation syndrome can be fatal if not treated. If differentiation syndrome is suspected, initiate corticosteroid therapy and hemodynamic monitoring until symptom resolution.

## Other relevant warnings and precautions:

- Risk of prolonged cardiac ventricular repolarization (QT interval). Perform ECG prior to initiation of treatment with XOSPATA, on days 8 and 15 of the first month, prior to the start of the next two months of treatment, and then as clinically indicated. Interrupt and/or reduce dosage in patients who have a QTcF >500msec.

- Risk of pancreatitis. Evaluate and monitor patients who develop signs and symptoms suggestive of pancreatitis. XOSPATA should be interrupted and can be resumed at a reduced dose when the signs and symptoms of pancreatitis have resolved.
- Risk of PRES: Uncommon events of posterior reversible encephalopathy syndrome (PRES) have been reported with symptoms including seizure and altered mental status. Discontinue XOSPATA in patients who develop PRES.
- Have the potential to influence the ability to drive and use machines.
- Can cause fetal harm when administered to a pregnant woman. Pregnancy testing is recommended for females of reproductive potential within 7 days prior to initiating treatment. Advise females of reproductive potential to use effective contraception during treatment and for at least 6 months after the last dose of XOSPATA.
- Advise males with female partners of reproductive potential to use effective contraception during treatment and for at least 4 months after the last dose of XOSPATA.
- No human data on the effect of XOSPATA on fertility are available. Based on findings in animal studies, XOSPATA may impair fertility in male patients of reproductive potential.
- Nursing women should be advised to discontinue breastfeeding during treatment and for at least 2 months after stopping XOSPATA.

## For more information:

Please consult the Product Monograph at [https://www.astellas.com/ca/system/files/2022-01-04\\_xospata\\_pm\\_-\\_english.pdf](https://www.astellas.com/ca/system/files/2022-01-04_xospata_pm_-_english.pdf) for important information about adverse reactions, drug interactions, and dosing information; particularly dosing considerations and dose modification recommendations not discussed in this piece. The Product Monograph is also available by calling 1-888-338-1824.

\* Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Ontario, Quebec, and Saskatchewan.<sup>2-19</sup> †Phase 3, open-label, multicentre, randomized clinical study of 371 patients with relapsed or refractory AML with a *FLT3* mutation. Patients were required to have *FLT3* ITD, TKD-D835 or TKD-I836 mutation determined by LeukoStrat CDx *FLT3* Mutation Assay at a central laboratory. Patients received XOSPATA 120 mg once daily until unacceptable toxicity or lack of clinical benefit (n = 247) or salvage chemotherapy (n = 124) which was selected by the local investigator before randomization from four possible options: mitoxantrone, etoposide, and cytarabine (MEC); fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA); low-dose cytarabine; and azacitidine. MEC and FLAG-IDA were considered to be high-intensity regimens, and low-dose cytarabine and azacitidine were considered to be low-intensity regimens. Dose reductions of XOSPATA were allowed. Some patients had their dose increased to 200 mg daily in the absence of a response; however, this is not an indicated dosage. The approved dose of XOSPATA is 120 mg daily. Overall survival (OS) was measured in time from the date of randomization until death by any cause.

**References:** 1. Current XOSPATA<sup>®</sup> Product Monograph, Astellas Pharma Canada, Inc. 2. Alberta Health Services Outpatient Cancer Drug Benefit Program. November 23, 2021. Available at: <https://www.albertahealthservices.ca/assets/programs/ps-1025651-drug-benefit-list.pdf> (accessed December 16, 2021). 3. British Columbia Cancer Benefit Drug List. March 2022. Available at: <http://www.bccancer.bc.ca/systemic-therapy-site/Documents/Policy%20and%20Forms/Benefit%20Drug%20List.pdf> (accessed March 4, 2022). 4. Manitoba Drug Benefits and Interchangeability Formulary Amendments. August 5, 2021. Available at: <https://www.gov.mb.ca/health/mdbif/docs/bulletins/bulletin112.pdf> (accessed December 16, 2021). 5. New Brunswick Drug Plans Formulary. March 4, 2022. Available at: <https://www2.gnb.ca/content/dam/gnb/Departments/h-s/pdf/en/NBDDrugPlan/NewBrunswickDrugPlansFormulary.pdf> (accessed March 4, 2022). 6. Newfoundland and Labrador Prescription Drug Program Drug Product Database. December 2021. Available at: [https://www.health.gov.nl.ca/health/prescription/class\\_search\\_nl.asp?din=02495058&GReturn=GenericName&Subtitle1=Generic%20or%20Brand%20Name%20-%20%20%20&Subtitle2=xospata](https://www.health.gov.nl.ca/health/prescription/class_search_nl.asp?din=02495058&GReturn=GenericName&Subtitle1=Generic%20or%20Brand%20Name%20-%20%20%20&Subtitle2=xospata) (accessed December 13, 2021). 7. Nova Scotia Formulary. February 2022. Available at: <https://novascotia.ca/dhw/pharmacare/documents/formulary.pdf> (accessed March 4, 2022). 8. Ontario Exceptional Access Program Reimbursement Criteria for Frequently Requested Drugs. January 1, 2022. Available at: [https://health.gov.on.ca/en/pro/programs/drugs/docs/frequently\\_requested\\_drugs.pdf](https://health.gov.on.ca/en/pro/programs/drugs/docs/frequently_requested_drugs.pdf) (accessed January 12, 2022). 9. Régie de l'assurance maladie du Québec. List of Medications (RAMQ): Official Mark of the Régie de l'assurance maladie du Québec. February 2, 2022. Available at: [https://www.ramq.gouv.qc.ca/sites/default/files/documents/liste\\_med\\_2022-02-02\\_en.pdf](https://www.ramq.gouv.qc.ca/sites/default/files/documents/liste_med_2022-02-02_en.pdf) (accessed March 4, 2022). 10. Saskatchewan Cancer Agency Drug Formulary. March 1, 2022. Available at: [http://www.saskcancer.ca/images/pdfs/health\\_professionals/drug\\_formulary/drug\\_formulary/SCA\\_Drug\\_Formulary\\_-\\_2022-03-01.pdf](http://www.saskcancer.ca/images/pdfs/health_professionals/drug_formulary/drug_formulary/SCA_Drug_Formulary_-_2022-03-01.pdf) (accessed March 4, 2022).



# A SINGULAR FOCUS ON CELL THERAPY

Every day, we strive to transform cancer care.  
It's what makes us who we are.

## What Science Can Do

AstraZeneca is proud to support the 2022 Canadian Association of Nurses in Oncology Conference as part of our commitment to improving the quality of life of people across Canada who are living with cancer.

At AstraZeneca, we believe in the power of what science can do to transform serious diseases like cancer, heart disease, diabetes, COPD, asthma, and the COVID-19 virus. Each and every one of us is bold in the belief that science should be at the centre of everything we do. It compels us to push the boundaries of what is possible: to trust in the potential of ideas and pursue them, alone and with others, until we have transformed the treatment of disease.





# JOIN US AT THE 35<sup>TH</sup> ANNUAL CANO/ACIO CONFERENCE

Niagara Falls, Ontario  
October 20-23, 2023

*Niagara Falls Marriott on the Falls &  
Scotiabank Convention Centre*

*Oncology Nursing: Strength Within*  
**Soins infirmiers oncologiques : Puiser la force en soi**

